



HAL
open science

DNA methylation in Schwann cells and in oligodendrocytes

Peter Arthur-Farraaj, Sarah Moyon

► **To cite this version:**

Peter Arthur-Farraaj, Sarah Moyon. DNA methylation in Schwann cells and in oligodendrocytes. *Glia*, 2022, 14 (8), pp.1568-1583. 10.1002/glia.23784 . hal-04146375

HAL Id: hal-04146375

<https://amu.hal.science/hal-04146375v1>

Submitted on 30 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

DNA methylation in Schwann Cells and in Oligodendrocytes

Glia Special Issue – Epigenetic Regulation of Glial Cell Identity and Function

P. Arthur-Farraj¹ and S. Moyon²

¹John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences
University of Cambridge, Robinson Way, Cambridge, CB2 0PY, UK

²Neuroscience Initiative Advanced Science Research Center, CUNY, 85 St Nicholas
Terrace, New York, NY 10031, USA

Corresponding authors: pja47@cam.ac.uk and smoyon@gc.cuny.edu

Authorship – Data availability

P.A-F and S.M both designed the figures, wrote and edited the paper. Data used for this review have been previously peer-reviewed and are referenced at the end of the manuscript.

Acknowledgements

Supported by the National Multiple Sclerosis Society (FG-1507-04996, S.M) and the Wellcome Trust (Clinical Research Career Development Fellowship 206634, P.A-F).

Conflict of Interest statement

The authors declare no conflicts of interest.

Word count

Total: 14,136

Main text: 6,696

Abstract

DNA methylation is one of many epigenetic marks, which directly modifies base residues, usually cytosines, in a multiple-step cycle. It has been linked to the regulation of gene expression and alternative splicing in several cell types, including during cell lineage specification and differentiation processes. DNA methylation changes have also been observed during aging, and aberrant methylation patterns have been reported in several neurological diseases. We here review the role of DNA methylation in Schwann cells and oligodendrocytes, the myelin-forming glia of the peripheral and central nervous systems, respectively. We first address how methylation and demethylation are regulating myelinating cells' differentiation during development and repair. We then mention how DNA methylation dysregulation in diseases and cancers could explain their pathogenesis by directly influencing myelinating cells' proliferation and differentiation capacities.

Keywords

DNA methylation, Oligodendrocyte, Schwann cell, Demyelination, Glioma, Schwannomas, Aging, Epigenetics


Main points

DNA methylation regulates Schwann cells and oligodendrocytes differentiation.

DNA modifications are necessary for myelination or remyelinating events in the CNS.

DNA methylation is dysregulated in myelinating glia in aging, in neurodegenerative diseases, and in Schwannomas and CNS gliomas.

TOCI



1. Introduction

Epigenetic regulation is composed of several layers of modifications, from regionally-restricted marks on DNA and histones, to more global remodeling of chromatin regions. DNA methylation is the first layer of these epigenetic processes, as it directly modifies base residues, on cytosines and to a lower extent on adenines. DNA modifications mainly target the cytosine residues at their C-5 position, essentially at CpG dinucleotides in mammalian genomes (Eden & Cedar, 1994; Lister et al., 2009). DNA methylation itself is a multi-step cycle, in which methylation is first initiated by the addition of a methyl group from S-adenosylmethionine on the C-5 position (5-methylcytosine, 5mC), then demethylation is gradually induced by the oxidation of 5mC to 5-hydroxy-methylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Hashimoto, Zhang, & Cheng, 2012; Huang & Rao, 2014; Lister et al., 2013; Meier & Recillas-Targa, 2017; H. Wu & Zhang, 2011) (**Figure 1A**). The first reaction is catalyzed by the DNA methyltransferases (DNMTs): the “maintenance” DNMT1, which is responsible for the faithful copying of DNA methylation from mother to daughter cells during replication, and the *de novo* DNMT3A and DNMT3B, which establish new methylation marks (Goll & Bestor, 2005; Lei et al., 1996; Lyko, 2018, p. 201; Okano, Xie, & Li, 1998). The demethylation reactions can be passive, but they are mainly catalyzed by the Ten-Eleven Translocations (TETs) enzymes, TET1, TET2 and TET3, which are differently expressed depending on the tissue type and also with age (Kriaucionis & Heintz, 2009; Rasmussen & Helin, 2016). The last demethylation step is catalyzed by thymine-DNA glycosylase (TDG), followed by base excision repair (BER) (**Figure 1A**).

DNA methylation has been shown to have important roles in X-inactivation, genomic imprinting, transposon silencing, transcription factor binding, cellular differentiation, cancer and aging (Beerman et al., 2013; M. J. Jones, Goodman, & Kobor, 2015; P. A. Jones, 2012; Yin et al., 2017). Generally, the level of methylation is higher in intergenic and repetitive regions of the genome and lower in gene regulatory areas, such as CpG islands (CGIs), transcription start sites, gene bodies and enhancer regions (P. A. Jones, 2012; Lister et al., 2009). At promoter regions and transcription starting sites, 5mC and 5hmC marks have mainly been associated with transcriptional

repression and initiation, respectively (Brenet et al., 2011; Schübeler, 2015; Smith & Meissner, 2013; Suzuki & Bird, 2008) (**Figure 1B**). Yet, while there is strong evidence for 5mC marks at CGIs at transcriptional start sites causing transcriptional repression, 5mC in other regions of the genome, particularly in enhancers and gene bodies, appears to be more dynamic and associated with both gene activation and repression (Deaton & Bird, 2011; P. A. Jones, 2012; Zhu, Wang, & Qian, 2016). Both 5mC and 5hmC marks could directly prevent the access of transcription factors to their binding sequence, especially for those containing a CG in their binding motif, or through binding partners such as methyl-CpG binding domain proteins. It is also worth noting that correlative assumptions between DNA methylation and gene expression have been recently challenged, as some studies have revealed modification of epigenetic marks following transcription. In these cases, DNA methylation and hydroxy-methylation marks would be revelators of ongoing or past gene expression and/or repression (Hodges et al., 2011; Lister et al., 2013; Stadler et al., 2011; Ziller et al., 2013). Specific DNA modifications could also recruit cofactors that modulate the chromatin environment, including histone modifications, which would imply a larger and more integrated role of several epigenetic marks in regulating gene expression (Jian Feng et al., 2015; Yiwei Liu, Zhang, Blumenthal, & Cheng, 2013; Schübeler, 2015; Smith & Meissner, 2013; Szulwach, Li, Li, Song, Han, et al., 2011; Yin et al., 2017). In gene bodies, 5mC and 5hmC marks have also been associated with alternative splicing (Gelfman, Cohen, Yearim, & Ast, 2013; Maunakea, Chepelev, Cui, & Zhao, 2013; Wan et al., 2013; Yearim et al., 2015). Less is known about the gene expression regulation by 5fC and 5caC marks, but the recent development of new sequencing methods and specific antibodies for these marks will certainly lead to a better characterization of their respective biological roles.

Methylation patterns remain reasonably static in terminally differentiated cells, whereas they are dynamically varied across cell types and developmental ages (J. Feng et al., 2010; Lister et al., 2013, 2009; Nestor et al., 2012, p. 201). During early cell lineage choice, in embryonic stem cells, binding sites of pluripotency-associated transcription factors have been shown to be enriched for DNA hydroxy-methylation (Ficz

et al., 2011). In the nervous system, DNA methylation has been extensively studied in neurons and astrocytes, which are both cell types that undergo several steps of lineage specification and cell differentiation (G. Fan et al., 2001; Guo et al., 2014; Hutnick et al., 2009; Kinde, Gabel, Gilbert, Griffith, & Greenberg, 2015; E. Li, Bestor, & Jaenisch, 1992; Milutinovic, Zhuang, Niveleau, & Szyf, 2003; Unterberger, Andrews, Weaver, & Szyf, 2006). During development, DNA methylation has been shown to be essential for determination of the neural lineage (Z. Wu et al., 2012), while demethylation has been reported to be associated with precocious astroglialogenesis, defective survival in proliferating neuroblasts and reduced neuronal plasticity in post-mitotic neurons (Guoping Fan et al., 2005; J. Feng et al., 2010; Hutnick et al., 2009; Z. Wu et al., 2012).

The myelinating cells of the peripheral nervous system (PNS) and the central nervous system (CNS), Schwann cells and oligodendrocytes, also undergo multiple cell lineage specification steps before terminally differentiating. A tight dynamic control of transcription factors is necessary for normal myelination, and their dysregulation, in cancers, diseases and aging, has been directly linked to glial cell proliferation or differentiation defects. Here, we review the role of DNA methylation in the Schwann cell and oligodendroglial lineages, during the myelination process in development and in the adult, as well as in injury, cancer and aging.

2. DNA methylation in Schwann Cells

2.1. The Schwann cell lineage

Schwann cells are amongst the major glial cell types of the mammalian PNS, alongside enteric glia from the gut and satellite glia from the dorsal root ganglia. Currently, there are four known types of Schwann cells, though this number will likely grow with future studies. Myelinating and Remak (non-myelinating) Schwann cells are found in spinal nerves and are associated with large and small caliber axons, respectively. Whereas terminal Schwann cells and nociceptive Schwann cells are associated with nerve terminals of motor and nociceptive neurons, respectively (Abdo et

al., 2019; Jessen & Mirsky, 2019). Schwann cells are generated from neural crest cells and pass through two well characterized developmental stages before differentiating into myelinating or Remak Schwann cells around birth. These stages are known as the Schwann cell precursor and the immature Schwann cell (Jessen & Mirsky, 2019).

More recently an additional Schwann cell state was identified. After injury to the adult PNS, myelinating and Remak Schwann cells transform into repair Schwann cells to promote nervous system regeneration (Arthur-Farraj et al., 2012; Gomez-Sanchez et al., 2017; Jessen & Arthur-Farraj, 2019). Repair Schwann cells can have subtly different molecular phenotypes depending on their vicinity to the site of injury (Clements et al., 2017). Following axon regeneration, they can re-differentiate into either myelinating or Remak Schwann cells, independent of their original phenotype (Stierli et al., 2018). Importantly, repair Schwann cells appear to be lineage-restricted and incapable of transforming into other cell types or of forming tumors, without further mutation or manipulation of their genome (Parfejevs, Antunes, & Sommer, 2018; Stierli et al., 2018).

2.2. DNA methylation regulates Schwann cell myelination

Both DNMT3A and DNMT3B are important for neural crest specification and the timing of their differentiation (for review see (Hu, Strobl-Mazzulla, & Bronner, 2014)). In the absence of *DNMT3A* in the chick embryo there is a failure to repress neural genes, *Sox 2* and *Sox3* in the prospective neural crest region and a subsequent loss of neural crest specifier genes, *Sox10*, *Foxd3* and *Snail2* (Hu, Strobl-Mazzulla, Sauka-Spengler, & Bronner, 2012). Loss of *DNMT3B* in both human embryonic stem cells and in the chick embryo leads to acceleration of neural crest differentiation and precocious peripheral neuronal differentiation (Hu, Strobl-Mazzulla, Simoes-Costa, Sánchez-Vásquez, & Bronner, 2014; Martins-Taylor, Schroeder, LaSalle, Lalande, & Xu, 2012). In the chick, *DNMT3B* binds and methylates the *Sox10* promoter, which represses *Sox10* expression, allowing for cessation of neural crest delamination (Hu, Strobl-Mazzulla, Simoes-Costa, et al., 2014). It is currently unknown whether DNA methylation regulates

the generation or behavior of Schwann cell precursors or Immature Schwann cells. Immature Schwann cells begin to myelinate after they select an axon through a process known as radial sorting (Monk, Feltri, & Taveggia, 2015). Schwann cells receive signals to myelinate from their basal lamina, most prominently through interaction of laminin-221 with the G-protein coupled receptor, GPR126, signaling through a cyclic AMP/protein kinase A axis (Mogha et al., 2013; Monk et al., 2009; Petersen et al., 2015). Additionally, Schwann cells also receive signals from the axon that regulate myelination, the most studied of these is Neuregulin 1 type III binding to ErbB receptors (Michailov et al., 2004; Taveggia et al., 2005). These signals coalesce on a number of transcription factors to regulate myelin gene expression, such as *Egr2/Krox-20* and *Yy1* ((Ye He et al., 2010), reviewed in (Herbert & Monk, 2017; Monk et al., 2015)).

Myelination begins in mouse nerves at birth (Monk et al., 2015). A genome wide CpG methylation study using reduced representation bisulfite sequencing compared mouse newborn nerves to adult mature myelinated postnatal day 60 (P60) nerves. They showed that promoter and regulatory regions for a number of myelin genes, such as *Mbp* and *Pmp22* became globally hypo-methylated by P60 and this broadly correlated with an up-regulation in myelin gene expression between these two time points. Moreover, binding sites for myelin-specific transcription factors, such as *Egr2* and *Yy1* were found to be enriched in the hypo-methylated regions (Varela-Rey et al., 2014) (**Figure 2**). It is important to note that the investigators found that, genome-wide, DNA hypo-methylation was associated with both up- and down-regulation of gene expression, which mirrors findings from other tissues (P. A. Jones, 2012). Although Varela-Rey et al. found that regulatory regions of a number of myelin genes became progressively more hypo-methylated, the relationship of DNA methylation with global myelin gene expression appears more complex. This is because most myelin genes were progressively up-regulated after birth (P10), while myelination proceeded, and then down-regulated again, albeit to levels higher than at newborn, in the adult nerve (P60) (Varela-Rey et al., 2014). Additionally, there are two further considerations to take into account with the interpretation of these findings. Firstly, Schwann cells are actively proliferating in the early postnatal nerve and this could certainly contribute to some of

the reduction in global CpG methylation observed in the adult nerve. Secondly, genome wide hypo-methylation is a phenomenon that is observed in many tissues with aging and it is possible that some of the hypo-methylation seen between newborn and P60 sciatic nerve could be related to the aging process (M. J. Jones et al., 2015). Despite this, genetically increasing the global level of DNA methylation in the mouse sciatic nerve through knockout of *Gnmt*, an enzyme that regulates the level of S-adenosylmethionine, the major methyl donor, led to thinner myelin sheaths and a reduction in expression of a number of lipid metabolism genes important in the myelination process (Varela-Rey et al., 2014) (**Figure 2**). This does demonstrate that altering methylation levels can regulate Schwann cell myelination *in vivo*, however it remains uncertain what the relative contribution of methylation of DNA versus histones contributes to this phenotype and whether it occurs through a Schwann cell autonomous mechanism.

Cyclic AMP has been identified as a signal that could regulate the level of DNA methylation in Schwann cells during myelination. Firstly, treating cultured Schwann cells with cyclic AMP analogues, an *in vitro* assay for myelin differentiation, induces global CpG hypo-methylation of the Schwann cell methylome (Varela-Rey et al., 2014). Additionally, it has been shown that elevation of cyclic AMP levels in Schwann cells, *in vitro*, can increase 5hmC in promoters and gene bodies of up-regulated myelin genes (e.g. *Prx* and *Mbp*), likely through increasing the bioavailability of TETs cofactor Fe^{2+} , in a process that is independent of protein kinase A activation (Camarena et al., 2017) (**Figure 2**). In support of this, the activity of TETs in the sciatic nerve significantly increases as myelination proceeds (Varela-Rey et al., 2014). Genome-wide profiling of 5hmC has yet to be performed in peripheral nerve but in the CNS, it has been shown that hydroxy-methylation is a relatively abundant epigenetic mark compared to other tissues and is enriched in enhancers and gene bodies while largely absent from transcriptional start sites (Szulwach, Li, Li, Song, Wu, et al., 2011).

While these studies implicate CpG methylation and potentially hydroxy-methylation in regulating myelination in the PNS, we still do not know the relative roles of the DNMTs and TETs enzymes in the Schwann cell lineage. Furthermore, it is likely

that global DNA hypo-methylation is not the principal molecular mechanism driving myelination but works in concert with histone modifications, transcription factor binding and microRNA mediated post-transcriptional processing, which all have substantial roles in initiating myelination (reviewed in this issue by N. Tapinos and C. Jacob, and by M. Wegner). Finally, single-cell methylome studies will be required to further clarify the methylome signature in the Schwann cell lineage and, in particular, how the methylome of Remak Schwann cells differs from that of myelinating Schwann cells in adult peripheral nerves.

2.3. Schwann cell methylome changes after nerve injury

Whole genome shotgun bisulfite sequencing of sciatic nerve seven days after nerve transection demonstrated relatively few methylation changes (853 differentially methylated CpGs out of over 4 million identified) compared to uninjured nerves (Arthur-Farraj et al., 2017). At this time point post-nerve injury, all Schwann cells are either in the process of or are already transformed into repair Schwann cells (Arthur-Farraj et al., 2012; Gomez-Sanchez et al., 2017). One caveat to this kind of analysis is that Schwann cells compose 80% of the uninjured and between 50-70% of the injured peripheral nerve, raising the possibility that other cell types could contribute to the methylation signatures. While this cannot be completely excluded without performing single cell methylation analysis, the *in vivo* methylation profile of the injured nerve was strongly correlated with the methylation profile of cultured Schwann cells (which have similar morphology and gene expression to repair Schwann cells) but not macrophages, cultured endoneurial fibroblasts or perineurial cells (Arthur-Farraj et al., 2017). Often, global methylation changes are the hallmark of loss of lineage restriction and tumorigenesis (Baylin & Jones, 2016). The fact that we detected relatively few methylation changes after injury might reflect the observation that myelinating and Remak Schwann cells remain lineage restricted after conversion to repair Schwann cells and are not multipotent (Stierli et al., 2018).

Schwann cells react to injury by down-regulating myelin genes and up-regulating developmental genes, alongside expression of a new program of genes specialized for repair (Jessen & Arthur-Farraj, 2019). Furthermore, repair Schwann cell morphology is radically different to that of immature Schwann cells (Gomez-Sanchez et al., 2017). In line with this, the DNA methylation changes occurring during myelination in development are not reversed upon injury, as one might expect if this was simply de-differentiation (Arthur-Farraj et al., 2017; Varela-Rey et al., 2014). Together, this shows that the Schwann cell reaction to injury cannot be classified solely as ‘de-differentiation’, which it is often referred to as, but instead as an adaptive change of cellular state, which is required to promote effective nerve repair (Jessen & Arthur-Farraj, 2019; Jessen, Mirsky, & Arthur-Farraj, 2015) (**Figure 2**).

Among the limited methylation changes observed in the injured nerve, the majority of differentially methylated regions (DMRs) were localized in regulatory regions of the genome, including putative enhancer regions. DMRs in these regions showed enrichment of genes associated with ErbB, TGF β and neurotrophin signaling, and occurred in the vicinity of binding sites for AP1 family, BACH2, MAFK and BATF transcription factors (Arthur-Farraj et al., 2017). Working in concert with other epigenetic modifications during nerve injury, DNA methylation changes may regulate expression of certain sets of genes through differential enhancer methylation and subsequent alteration of transcription factor binding. Conversely, altered methylation may occur as a result of transcription factor binding (Schübeler, 2015). The DNA demethylase, TET2 has been identified as having an important role in regulating enhancer methylation (Lister et al., 2013). In light of this, it would be particularly interesting to investigate whether TET2 and have a role in regulating demethylation/hydroxy-methylation at enhancers in Schwann cells.

3. DNA methylation in oligodendrocytes

3.1. The oligodendroglial cell lineage

Oligodendrocytes (OLs), the myelinating cells of the CNS, emerge from oligodendrocyte progenitor cells (OPCs), themselves deriving from neural stem cells. The switch from highly proliferative and migrative cells, characteristic of OPCs, to differentiating and ensheathing cells, specific to OLs, is regulated by the dynamic and orchestrated expression of specific transcription factors, from early specification (e.g. *Ascl1*, *Olig1/Olig2*, *Sox10*) to late maturation (e.g. *Yy1*, *Myrf*, *Zfp191*) (Emery et al., 2009; Y. He et al., 2007; Howng et al., 2010; Küspert & Wegner, 2016; Q. R. Lu et al., 2002; Nakatani et al., 2013). These processes are also regulated by epigenetic modifications, including chromatin remodeling (reviewed in this issue by C. Parras and QR. Lu), histones modifications (reviewed in this issue by J. Liu and G. Castelo-Branco) and DNA methylation.

3.2. DNA methylation in oligodendroglial cells during developmental myelination

DNA modification enzymes, DNMTs and TETs, are highly enriched in brain, liver and reproductive tissues, which correlate with high DNA methylation and hydroxymethylation levels in the CNS, compared to other tissues (Globisch et al., 2010; W. Li & Liu, 2011; Ono, Uehara, Kurishita, Tawa, & Sakurai, 1993; Szulwach, Li, Li, Song, Wu, et al., 2011; Tawa, Ono, Kurishita, Okada, & Hirose, 1990). However, their levels at specific genomic regions dynamically vary during oligodendroglial cell development, from their specification to their differentiation.

In early developmental stages, specification of cortical neural stem cells into the glial lineage has been shown to be regulated by two successive DNA methylation waves, first global demethylation, followed by specific methylation and silencing of neuronal genes (Guo et al., 2014; Oswald et al., 2000; Sanosaka et al., 2017; Z. Wu et al., 2012). Low-methylated regions at promoters of astrocyte- and oligodendrocyte-specific genes are also enriched for gliogenic transcription factors, such as the nuclear factor I-binding motif, which are necessary to drive glial specification (Guoping Fan et al., 2005; Namihira et al., 2009; Sanosaka et al., 2017; Shu, Butz, Plachez,

Gronostajski, & Richards, 2003). Finally, acquisition of *de novo* methylation and hydroxy-methylation at specific astroglial (e.g. *Gfap*, genes involved in the JAK-STAT pathway) and oligodendroglial (e.g. *Olig1*, *Sox10*, *Id2/4*) genes distinguishes between these two glial lineages (Guoping Fan et al., 2005; Hatada et al., 2008; Takizawa et al., 2001; Teter et al., 1996; H. Wu et al., 2010; M. Zhang et al., 2019) (**Figure 3**).

The dynamic levels of DNA methylation and hydroxy-methylation in the oligodendroglial lineage, as well as their respective catalytic enzymes, DNMTs and TETs, suggest that these epigenetic marks are also essential for oligodendrocyte differentiation (Moyon et al., 2016; Y. Zhang et al., 2014; Zhao et al., 2014). An initial descriptive study detected a specific demethylation of the myelin gene, *Mag*, during OPC differentiation (Grubinska, Laszkiewicz, Royland, Wiggins, & Konat, 1994). Indeed, TET1, TET2 and TET3 have been shown to be necessary for OPC differentiation *in vitro* (Zhao et al., 2014). On the contrary, the blockade of the DNA methylation enzymes, *in vivo*, during rat CNS development, has been shown to delay myelination (Ransom, Yamate, Black, & Waxman, 1985). However, this study was using a non-specific demethylating drug, which also affected RNA metabolism and post-transcriptional processes. More detailed whole-genome methylome analysis comparing sorted neonatal OPCs and OLs has shown that OPC differentiation is associated with the same extent of hypo- as hyper-methylation. DNA methylation marks, identified by bisulfite-conversion sequencing, are mainly inversely correlated with gene expression during developmental myelination: genes with hypermethylated promoters and decreased expression in OLs compared to OPCs are associated with “neuronal lineage”, “cell cycle regulation” and “proliferation”, while genes with hypomethylated promoters and increased expression in OLs compared to OPCs are associated with “lipid processes” and “myelin components”. Decreasing methylation of differentiation genes after genetic ablation of *Dnmt1* in OPCs was not sufficient to induce their differentiation, as it was also associated with reduced methylation and hence defective repression, of cell cycle genes and activation of genotoxic stress and the ER stress response. Conversely, RNA-Sequencing of *in vitro* OPCs lacking *Tet1* revealed that downregulated genes were enriched for differentiation and cell cycle regulation genes.

However, loss of *Tet1* in neonatal OPC was not sufficient to block their proliferation and differentiation *in vitro* and *in vivo* (Moyon et al., 2019; M. Zhang et al., 2019). This highlights a more complex role for DNA methylation in the oligodendroglial lineage, requiring both methylation and demethylation of specific genomic regions (**Figure 3**). Further analysis of the RNA-Sequencing of sorted control and *Dnmt1*-mutant OPCs also identified different alternative splicing events, correlated with massive hypo-methylation at the exon-intron boundaries (Moyon et al., 2016). On one hand, alternative splicing events have been shown to be necessary for oligodendrocyte differentiation during normal myelination (de Ferra et al., 1985; Jordan et al., 1990; Kevelam et al., 2015; Nave, Lai, Bloom, & Milner, 1987; Y. Zhang et al., 2014), and on the other hand, to be correlated with DNA methylation marks (Gelfman et al., 2013; Lev Maor, Yearim, & Ast, 2015; Wan et al., 2013; Yearim et al., 2015). In OPCs, the gene ontology of the alternative spliced transcripts is enriched for genes involved in the cell cycle process and myelination (Moyon et al., 2016). This shows that DNA methylation and demethylation directly affect gene expression and alternative splicing in OPCs, and are both required for normal myelination.

Functional studies suggest specific roles for each DNMTs and TETs in the oligodendroglial lineage during development. Recently, *in vitro* loss-of-function experiments have shown that DNMT3A may participate in OPC survival and proliferation, while DNMT1 might be necessary for OPC differentiation (Egawa et al., 2019). DNMT1 could also affect oligodendroglial cells survival *in vitro*, as it has already been observed in embryonic stem cell, but these results were not duplicated *in vivo* (Egawa et al., 2019; Liao et al., 2015). Indeed, the genetic ablation of *Dnmt1* only – and not *Dnmt3a* – *in vivo* in OPCs (using *Olig1-cre* line) resulted in a severe hypomyelination of the CNS, associated with tremors and decreased survival. In OPCs lacking *Dnmt1*, neither cell lineage specification nor survival were affected but, despite the hypomethylation of myelin genes, OPCs did not precociously proliferate or differentiate. Genetic ablation of *Dnmt1* or *Dnmt3a*, *in vivo*, in later stages of OL development (using *Cnp-cre* line) did not show any phenotype, which suggested that DNA methylation might only be required in the early steps of OPC differentiation *in vivo*

(Moyon et al., 2016). This discrepancy suggests that *in vitro* and *in vivo* DNA methylation mechanisms might be slightly different, since epigenetic modifications can reflect extra-cellular and environmental cues. To better correlate and understand the role of DNA methylation on gene expression and alternative splicing, it would also be necessary to analyze the different DNA methylation marks at the single-cell level in these knock-out mouse lines. Concerning DNA hydroxy-methylation, loss of *Tet2* or *Tet3* in the oligodendroglial lineage during developmental myelination did not show any phenotypes (Moyon et al., 2019; M. Zhang et al., 2019). While *in vivo* ablation of *Tet1* in OPCs (using *Olig1-cre* line) appears to result in a lower number of embryonic OPCs and slightly delayed OL differentiation at early stages (post-natal day 14), only in brain regions, the extent of the myelination and its ultra-structure in adult animals are comparable to controls (post-natal day 60) (M. Zhang et al., 2019). This would suggest that DNA hydroxy-methylation and its respective enzymes are not required for neonatal OPC differentiation during developmental myelination.

3.3. DNA methylation in oligodendroglial cells, in adult and aging

During development, a pool of undifferentiated adult OPCs is maintained and uniformly distributed in the grey and white matter of the adult CNS (Chang, Nishiyama, Peterson, Prineas, & Trapp, 2000; Dawson, Polito, Levine, & Reynolds, 2003; Pringle, Mudhar, Collarini, & Richardson, 1992; Wolswijk & Noble, 1989). Adult OPCs are not only immature and on-standby cells, as once thought. More and more evidence has confirmed their essential roles in the adult CNS, which includes directly regulating neuronal, glial and vascular systems (Frühbeis et al., 2013; Gautier et al., 2015; Hayakawa et al., 2011; Pham et al., 2012). They are also the main myelinating cells of the adult CNS, necessary for myelin remodelling, plasticity, learning and for remyelination (Bengtsson et al., 2005; Fancy et al., 2011; I. A. McKenzie et al., 2014; Young et al., 2013). However, adult OPCs have different proliferation, migration and differentiation capacities than neonatal OPCs, which result from their different transcriptomic profiles (Chari, Crang, & Blakemore, 2003; Clarke et al., 2012; Lin, Mela,

Guilfoyle, & Goldman, 2009; Marques et al., 2016; Moyon et al., 2015; Spitzer et al., 2019). Many epigenetic marks have been demonstrated to change with aging, but DNA methylation, especially, has been identified as the prominent epigenetic clock or age predictor (Bell et al., 2012; Hernandez et al., 2011; Horvath, 2013; Horvath & Raj, 2018; Masser et al., 2018; Shen et al., 2008; Stubbs et al., 2017; Szulwach, Li, Li, Song, Wu, et al., 2011; Unnikrishnan et al., 2019). This suggests that phenotypic differences observed between adult OPCs and neonatal OPCs could also reflect age-related methylomic changes.

The role of DNA methylation and DNMTs has recently been reported *in vivo* in adult OPCs during remyelination. Genetic ablation of *Dnmt1* and/or *Dnmt3a* in the oligodendroglial lineage impairs OPC differentiation into mature OLs, leading to thinner and delayed remyelination, following lysolecithin-induced focal demyelination in ventral spinal cords (Moyon et al., 2017). Interestingly, loss of a single *Dnmt* is less dramatic than loss of both *Dnmt1* and *Dnmt3a*, suggesting compensatory or redundant roles for DNMTs in adult OPCs, an observation not seen in neonatal OPCs. The lack of *Dnmt1* reduced differentiation in both neonatal and adult OPCs, but only proliferation in neonatal OPCs (Moyon et al., 2016, 2017) (**Figure 3**). This suggests an age-dependent role for DNA methylation in OPC differentiation. One caveat with this conclusion is that the neonatal and adult studies used slightly different genetic strategies (i.e. *Olig1-cre* line targeting early progenitors in developmental brain and *Pip-cre* line targeting newly formed oligodendrocytes in adult brain), so the effects observed on the cell cycle may simply reflect the distinct proliferative potential of these two targeted cell populations, and not only their age-related differences (Moyon et al., 2016, 2017). Future parallel studies comparing the contribution of DNA methylation to neonatal and adult progenitor function are needed to fully address these issues.

In adult human tissues, TET genes have been shown to be enriched in the oligodendroglial lineage compared to neuronal subtypes. DNA methylation and hydroxy-methylation levels appear to be cell type-specific in the adult CNS, which might suggest an interesting specification role in each cell lineage, including oligodendrocytes (Kozlenkov et al., 2018). Recent studies have functionally shown that TET1 – and not

TET2 or TET3 – is the main DNA hydroxy-methylation enzyme regulating adult OPC differentiation (Moyon et al., 2019; M. Zhang et al., 2019). Following lysolecithin-induced lesion in young adult ventral spinal cords, efficient remyelination appears to be correlated with high TET1 expression and increased DNA hydroxy-methylation in the oligodendroglial population. Moreover, ablation of *Tet1* in the oligodendroglial lineages impaired OL differentiation and delayed remyelination. In aging mice, defective remyelination was also associated with lower TET1 expression and no increased DNA hydroxy-methylation in the oligodendroglial cells. Interestingly, impaired remyelination observed in young mice lacking *Tet1* seems to recapitulate the hallmarks of an aging phenotype, such as delayed repair and ultra-structural peri-axonal swellings, which would eventually lead to defective neuronal functions (Moyon et al., 2019). Altogether, these new evidences highlight the essential role of TET1-mediated DNA hydroxy-methylation in adult OPC, especially after injury, and its potentially deleterious role during aging repair.

3.4. DNA methylation in oligodendroglial cells in diseases

Epigenetic mechanisms, including DNA methylation, have particular relevance for human neurodegenerative and psychiatric disease. The development of genome-wide DNA methylation studies of human post-mortem brain tissues has highlighted methylation and demethylation changes in Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis and schizophrenia (Chestnut et al., 2011; Desplats et al., 2011; Jaffe et al., 2015; P. Li et al., 2019; Semick et al., 2019). These datasets have mainly been performed on whole-tissue, and their analysis have followed an historically neuro-centric hypothesis. Though previously overlooked, the role of oligodendroglial cells in neurological disorders has recently been the focus of a number of studies (Chen, Huang, Michael, & Xiao, 2015; A. T. McKenzie et al., 2017; Nasrabady, Rizvi, Goldman, & Brickman, 2018; Nguyen et al., 2013). New single-nucleus isolation and sequencing technology have now noted specific DNA methylation changes in oligodendroglial populations in Alzheimer's disease and in schizophrenia. In these

studies, DNA methylation changes appeared to be as frequently represented in the oligodendroglial population as in the neuronal population, but occurring at different genomic regions between the two cell populations (Gasparoni et al., 2018; Mendizabal et al., 2019). DNA methylation dysregulation in OPCs and OLs could be associated with several pathologies, as patients with deficiency in S-adenosylhomocysteine hydrolase have been observed to also present correlative CNS hypomyelination (Barić et al., 2004).

Indeed, alterations in DNA methylation have been reported in diseases that affect the oligodendroglial lineage, such as Multiple Sclerosis (MS). MS is a common immune-mediated CNS disease, characterized by oligodendroglial loss and focal attacks of demyelination, which are frequently associated with neurodegeneration (Ghosh et al., 2011; International Multiple Sclerosis Genetics Consortium*†, 2019; Oluich et al., 2012). A recent study has shown that *DNMTs* are up-regulated and *TETs* down-regulated in demyelinated areas of the hippocampus from MS patients, which would suggest that one would expect an increase in methylation in MS tissues (Chomyk et al., 2017). However, DNA methylation sequencing of MS-affected brain tissues revealed a variety of methylomic changes in MS-affected normal appearing white matter (NAWM) and hippocampus compared to controls. For example, genes known to regulate oligodendroglial survival and differentiation (i.e. *BCL2L2*, *NDRG1*, *NFASC*) are hyper-methylated and down-regulated in MS NAWM samples, which could affect the OPCs' response capacities and overall remyelination in patients (Chomyk et al., 2017; Huynh et al., 2014). In contrast, genes implicated in proteolytic processing (i.e. *LGMMN*, *CTSZ*, *PAD2*) are hypo-methylated and up-regulated in MS NAWM samples, which could even have the capacity to trigger the disease (Chomyk et al., 2017; Huynh et al., 2014; Mastronardi, Noor, Wood, Paton, & Moscarello, 2007). Indeed, *PAD2* can citrullinate myelin basic protein (MBP), which results in the breakdown of myelin, the release of myelin protein fragments and a subsequent immune response (Mastronardi & Moscarello, 2005; Mastronardi et al., 2006). Citrullination of MBP has been shown to be elevated in MS tissues compared to controls, which directly correlates with hypo-methylation and up-regulation of *PAD2*, and with increased levels of *PAD2* enzyme

(Mastronardi et al., 2007; Moscarello, Wood, Ackerley, & Boulias, 1994). These findings suggest that complex DNA methylation changes in OPCs and OLs could contribute to MS pathology, possibly by affecting both demyelination and remyelination. Knowing the predominant incidence of MS in women compared to men, it is also worth noting that a recent study has shown that DNA methylation changes observed during aging in mouse hippocampus were sex-specific. DNA methylation did not differ between males and females in young tissues but more than 95% of age-related changes occurred in methylation at specific sites in one sex but not the other (Masser et al., 2017). Further oligodendroglial-specific and sex-specific analysis would be interesting to address the potential role of DNA methylation in MS incidence and pathology.

4. The role of DNA methylation in Schwann cell and oligodendroglial tumors

4.1. Glial origin of some PNS and CNS tumors

The main Schwann cell tumors are benign Schwannomas and neurofibromas, and malignant peripheral nerve sheath tumors (MPNST) (for reviews see (Evans et al., 2002; Hilton & Hanemann, 2014; Ratner & Miller, 2015)). The commonest genetic abnormality found in sporadic Schwannomas is mutation in the *NF2* gene, which codes for the protein, Merlin (Hilton & Hanemann, 2014). Patients with neurofibromatosis type 1 (NF1), develop amongst other neoplasms, cutaneous and plexiform neurofibromas, which are thought to be predominantly Schwann cell tumors but which also contain other cell types. All neurofibromas are associated with bi-allelic inactivation of the *NF1* gene, which codes for the tumor suppressor protein, neurofibromin, an inhibitor of RAS signaling (Ratner & Miller, 2015). In a proportion of NF1 patients, plexiform neurofibromas will transform into MPNSTs, however 50% of MPNST do occur sporadically. These tumors are highly aggressive and generally have a poor prognosis (Farid et al., 2014).

Gliomas are the most common type of primary brain tumors in adults and they are usually characterized by poor prognoses (Ohgaki & Kleihues, 2005). Molecular

characterization of gliomas suggest that they originate from proliferative cells, such as neural stem cells, astrocytes and OPCs (for review see (Zong, Parada, & Baker, 2015)). Histopathological analysis of human glioma samples (e.g. expression of OPC-specific markers, such as NG2 and Olig2) and analysis of the molecular signature of proneural glioblastomas (e.g. expression of *PDGFR α* , *NKX2-2*, *OLIG2*) strongly suggest an oligodendroglial origin (Ligon et al., 2004; Q. Richard Lu et al., 2001; Shoshan et al., 1999; Verhaak et al., 2010). Proneural gliomas present alterations of *PDGFR α* , such as mutations and/or amplifications, often associated with point mutations in tumor protein gene *TP53* and in isocitrate dehydrogenase (IDH) 1 (Verhaak et al., 2010). Interestingly, three recent studies even highlighted the synaptic interaction of OPC-like cells with neural circuits in gliomas, which might promote their progression (Venkataramani et al., 2019; Venkatesh et al., 2019; Zeng et al., 2019).

4.2. Aberrant DNA modifications in Schwannomas and glioblastomas

Aberrant DNA methylation is strongly implicated in tumorigenesis. There are three ways DNA methylation can contribute to an oncogenic phenotype: firstly by enabling somatic and germline mutation through deamination of 5mC to thymine within gene bodies, following exposure to UV irradiation or carcinogens; secondly by global hypo-methylation; and thirdly by hyper-methylation of CGI promoters of tumor suppressor genes (Baylin & Jones, 2016).

In some gliomas, OPC proliferation and apoptosis dysregulation has been directly linked to mutation of genes involved in the DNA methylation/demethylation cycle. IDH1/2 mutation, which is frequently detected in these types of cancers, has been shown to induce the accumulation of 2-Hydroxyglutarate, inhibiting Alpha-Ketoglutarate-dependent deoxygenase and the metabolic-epigenetic interplay, leading to alteration of both histone and DNA methylation patterns (Christensen et al., 2011; Ohba & Hirose, 2018; Unruh et al., 2019; Yan et al., 2009).

Many tumors, and especially gliomas, have been characterized by extensive global DNA hypo-methylation, associated with aberrant activation of genes and non-coding regions (Chou et al., 2012; Chu et al., 2011; Felsberg et al., 2006; Jia et al., 2019; Sharma, Kelly, & Jones, 2010; Uhlmann et al., 2003; Watanabe & Maekawa, 2010; J. Zhang et al., 2016). Inversely, 5hmC enrichment, potentially allowing gene expression activation, has also been detected in enhancers implicated in glioma pathogenesis (Glowacka et al., 2018; Johnson et al., 2016). A number of studies have also shown that the significant DNA methylation changes observed in Schwann cell tumors are likely to contribute to their pathogenesis, as well as aid in their classification. Firstly, the global methylation profiles of Schwannomas differ based on their anatomical location, as cranial Schwannomas show different methylation patterns to spinal Schwannomas (Agnihotri et al., 2016). Genome-wide methylation mapping using MeDIP-Seq, which immunoprecipitates methylated DNA prior to whole genome sequencing, compared the methylome of benign Schwannomas, MPNSTs and cultured human Schwann cells. This study found over 100,000 DMRs between samples, including hyper-methylation of tumor suppressor genes, hypo-methylation of oncogenes and differential methylation of CGI shores. Yet, the most common methylation change was hypo-methylation of non-intronic satellite regions, particularly SATR1 and ARLalpha satellite repeat regions (Feber et al., 2011). Microsatellite instability does not appear to be a frequent aberration in MPNSTs suggesting that hypo-methylation of these regions may have a more complex role, possibly in the regulation of nearby genes, though this remains to be tested (Serra et al., 1997). A genome-wide methylation microarray of vestibular Schwannomas demonstrated a trend towards hypo-methylation with more differential methylation identified away from CGIs, similar to the findings in MPNSTs (Feber et al., 2011). Significant hypo-methylation of the *Hox* gene cluster was identified as a commonly occurring alteration but this study did not identify any *NF2* promoter hypermethylation, unlike previously (Feber et al., 2011; Gonzalez-Gomez, Bello, Arjona, et al., 2003; Torres-Martín et al., 2015).

In parallel, tumors, such as gliomas, have been characterized by regional DNA hyper-methylation at specific loci, correlated with silencing of tumor suppressor genes

(Chou et al., 2012; Chu et al., 2011; Felsberg et al., 2006; Jia et al., 2019; Sharma et al., 2010; Uhlmann et al., 2003; Watanabe & Maekawa, 2010; J. Zhang et al., 2016). In Schwannomas and MPNSTs, a number of early and targeted studies have also identified promoter hyper-methylation of tumor suppressor genes and their subsequent inactivation, which appeared as potential mechanism for how aberrant DNA methylation contributes to tumorigenesis (Gonzalez-Gomez, Bello, Alonso, et al., 2003; Gonzalez-Gomez, Bello, Arjona, et al., 2003; Kawaguchi et al., 2006; Kino et al., 2001; Oh et al., 2015). Promoter hyper-methylation of the downstream effectors of Merlin/NF2, *Lats1* or *Lats2*, has been described in Schwannomas and it was recently shown in mice that specific deletion of both *Lats1* and *Lats2* in Schwann cells can lead to MPNST generation (Oh et al., 2015; L. M. N. Wu et al., 2018). In contrast to *Nf2*, hyper-methylation of the *Nf1* promoter does not seem to occur in Schwann cell tumors (Feber et al., 2011; Fishbein, Eady, Sanek, Muir, & Wallace, 2005; Harder et al., 2004; Luijten et al., 2000). However, site specific methylation of discrete CpGs in *SP1*, *AP2* and *CRE* binding sites in the *Nf1* promoter may affect transcription factor binding and *NF1* expression in neurofibromas and MPNSTs (Harder et al., 2004; Kino et al., 2001; Mancini, Singh, Archer, & Rodenhiser, 1999).

DNA methylation modifications have been highly correlated with tumorigenesis and prognosis of Schwannomas, MPNSTs, and gliomas, which suggests that specific methylating and demethylating agents could be potential therapies to prevent cancer cell progression in these tumours (Aoki & Natsume, 2019; de Souza et al., 2018; Heiland et al., 2016; Yanwei Liu et al., 2015; Ohba & Hirose, 2018). Certainly epigenetic therapies targeting the polycomb repressive complex 2 (PRC2) are a promising current avenue of research for MPNSTs and high grade gliomas given genetic studies strongly implicate PRC2 and loss of Histone H3K27 methylation in their progressions (De Raedt et al., 2014; Filbin et al., 2018; Lee et al., 2014; Nagaraja et al., 2017; Natalie Wu & Lu, 2019; M. Zhang et al., 2014). Presently, the main challenges facing the field are to discern whether the differential methylation observed in tumors are more cause or consequence of the oncogenic process. Furthermore, what role does the DNA methylation machinery have in the development of Schwannomas, MPNSTs and

gliomas? Finally, we still don't understand the hierarchical interaction between DNA methylation, histone modifications and chromatin states within individual tumor cells and this needs to be addressed to develop better future treatments (Baylin & Jones, 2016).

5. Concluding remarks

A growing body of evidence supports a prominent role for both DNA methylation and potentially DNA hydroxy-methylation in Schwann cells and oligodendroglial cells lineages, during development and in a number of neurological diseases, including tumors. A better integration of these specific 5mC and 5hmC marks with other epigenetic layers, such as histone modifications, chromatin remodeling or microRNA post-transcriptional processing, would be essential to clearly map their respective roles on gene regulation during myelinating cells proliferation and differentiation processes. New tools, including specific 5fC and 5caC antibodies and sequencing techniques, should also now allow a better comprehension of these DNA modifications marks. Single-cell sequencing coupled with methylome analysis would be essential to precisely address the functional role of epigenetic marks, which are highly specific between each cell type and within each cellular lineage, between developmental times and within aging, injury and disease.

Figures



Figure 1. DNA methylation/demethylation cycle

(A) A class of enzymes called DNA methyltransferases (DNMT1, DNMT3A, 3B) methylate cytosines (C) by transferring a methyl group from S-adenosylmethionine (SAMe). 5-methylcytosine (5mC) can be oxidized by ten eleven translocation (TET) enzymes (TET1, TET2, TET3) to 5-hydroxy-methylcytosine (5hmC), to 5-formylcytosine (5fC), then 5-carboxylcytosine (5caC). The last demethylation step is catalyzed by thymine-DNA glycosylase (TDG), followed by base excision repair (BER). **(B)** Generally, DNA methylation (5mC) marks are associated with gene repression, while DNA hydroxy-methylation (5hmC) marks are correlated with gene expression.




Figure 2. DNA methylation in Schwann cells during myelination and after nerve injury.

The transition from immature Schwann cell to myelinating Schwann cell is accompanied by hypomethylation of promoters and enhancers of myelin and lipid biosynthetic pathway genes. The DNA methyltransferase, Glycine N-methyltransferase (GNMT), which metabolizes S-Adenosylmethionine (SAmE), positively regulates the myelination process, whereas increases in the levels of SAmE negatively regulate myelination (Varela-Rey et al., 2014). The transformation of myelinating Schwann cells to Repair Schwann cells after nerve injury is accompanied by down-regulation of myelin genes, up-regulation of developmental genes and also of repair program genes (Jessen & Arthur-Farraj, 2019). There are no global methylome changes in Schwann cells upon nerve injury but discrete differential methylation in putative repair program gene enhancers (Arthur-Farraj et al., 2017).




Figure 3. DNA methylation in oligodendroglial cell differentiation during myelination and remyelination.

Oligodendroglial cell lineage differentiation is regulated by both DNA methylation and demethylation. Early DNA methylation of neuronal and astroglial lineage genes induce oligodendroglial specification. During oligodendrocyte progenitor cell differentiation, DNA methylation – mediated by DNMT1 during development and mainly DNMT3A in adult - has been associated with transcriptional repression of proliferation genes and of inhibitor of differentiation genes. In contrary, DNA demethylation has been observed on differentiation and myelin genes, resulting from TET activity that induces the OPC differentiation program, during developmental myelination and repair.

References

- Abdo, H., Calvo-Enrique, L., Lopez, J. M., Song, J., Zhang, M.-D., Usoskin, D., ... Ernfors, P. (2019). Specialized cutaneous Schwann cells initiate pain sensation. *Science*, *365*(6454), 695–699. <https://doi.org/10.1126/science.aax6452>
- Agnihotri, S., Jalali, S., Wilson, M. R., Danesh, A., Li, M., Klironomos, G., ... Zadeh, G. (2016). The genomic landscape of schwannoma. *Nature Genetics*, *48*(11), 1339–1348. <https://doi.org/10.1038/ng.3688>
- Aoki, K., & Natsume, A. (2019). Overview of DNA methylation in adult diffuse gliomas. *Brain Tumor Pathology*, *36*(2), 84–91. <https://doi.org/10.1007/s10014-019-00339-w>
- Arthur-Farraj, P. J., Latouche, M., Wilton, D. K., Quintes, S., Chabrol, E., Banerjee, A., ... Jessen, K. R. (2012). C-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration. *Neuron*, *75*(4), 633–647. <https://doi.org/10.1016/j.neuron.2012.06.021>
- Arthur-Farraj, P. J., Morgan, C. C., Adamowicz, M., Gomez-Sanchez, J. A., Fazal, S. V., Beucher, A., ... Aitman, T. J. (2017). Changes in the Coding and Non-coding Transcriptome and DNA Methylome that Define the Schwann Cell Repair Phenotype after Nerve Injury. *Cell Reports*, *20*(11), 2719–2734. <https://doi.org/10.1016/j.celrep.2017.08.064>
- Barić, I., Fumić, K., Glenn, B., Čuk, M., Schulze, A., Finkelstein, J. D., ... Mudd, S. H. (2004). S-adenosylhomocysteine hydrolase deficiency in a human: A genetic disorder of methionine metabolism. *Proceedings of the National Academy of Sciences*, *101*(12), 4234–4239. <https://doi.org/10.1073/pnas.0400658101>
- Baylin, S. B., & Jones, P. A. (2016). Epigenetic Determinants of Cancer. *Cold Spring Harbor Perspectives in Biology*, *8*(9). <https://doi.org/10.1101/cshperspect.a019505>
- Beerman, I., Bock, C., Garrison, B. S., Smith, Z. D., Gu, H., Meissner, A., & Rossi, D. J. (2013). Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. *Cell Stem Cell*, *12*(4), 413–425. <https://doi.org/10.1016/j.stem.2013.01.017>
- Bell, J. T., Tsai, P.-C., Yang, T.-P., Pidsley, R., Nisbet, J., Glass, D., ... Deloukas, P. (2012). Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population. *PLoS Genetics*, *8*(4), e1002629. <https://doi.org/10.1371/journal.pgen.1002629>
- Bengtsson, S. L., Nagy, Z., Skare, S., Forsman, L., Forssberg, H., & Ullén, F. (2005). Extensive piano practicing has regionally specific effects on white matter development. *Nat Neurosci*, *8*(9), 1148–1150. <https://doi.org/10.1038/nn1516>
- Brenet, F., Moh, M., Funk, P., Feierstein, E., Viale, A. J., Socci, N. D., & Scandura, J. M. (2011). DNA Methylation of the First Exon Is Tightly Linked to Transcriptional Silencing. *PLOS ONE*, *6*(1), e14524. <https://doi.org/10.1371/journal.pone.0014524>
- Camarena, V., Sant, D. W., Huff, T. C., Mustafi, S., Muir, R. K., Aron, A. T., ... Wang, G. (2017). CAMP signaling regulates DNA hydroxymethylation by augmenting the intracellular labile ferrous iron pool. *ELife*, *6*, e29750. <https://doi.org/10.7554/eLife.29750>
- Chang, A., Nishiyama, A., Peterson, J., Prineas, J., & Trapp, B. D. (2000). NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. *J Neurosci*, *20*(17), 6404–6412.
- Chari, D. M., Crang, A. J., & Blakemore, W. F. (2003). Decline in rate of colonization of oligodendrocyte progenitor cell (OPC)-depleted tissue by adult OPCs with age. *J Neuropathol Exp Neurol*, *62*(9), 908–916.
- Chen, X.-S., Huang, N., Michael, N., & Xiao, L. (2015). Advancements in the Underlying Pathogenesis of Schizophrenia: Implications of DNA Methylation in Glial Cells. *Frontiers in Cellular Neuroscience*, *9*. <https://doi.org/10.3389/fncel.2015.00451>
- Chestnut, B. A., Chang, Q., Price, A., Lesuisse, C., Wong, M., & Martin, L. J. (2011). Epigenetic regulation of motor neuron cell death through DNA methylation. *The Journal of Neuroscience*:

The Official Journal of the Society for Neuroscience, 31(46), 16619–16636. <https://doi.org/10.1523/JNEUROSCI.1639-11.2011>

Chomyk, A. M., Volsko, C., Tripathi, A., Deckard, S. A., Trapp, B. D., Fox, R. J., & Dutta, R. (2017). DNA methylation in demyelinated multiple sclerosis hippocampus. *Scientific Reports*, 7(1), 8696. <https://doi.org/10.1038/s41598-017-08623-5>

Chou, A. P., Chowdhury, R., Li, S., Chen, W., Kim, A. J., Piccioni, D. E., ... Lai, A. (2012). Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas. *Journal of the National Cancer Institute*, 104(19), 1458–1469. <https://doi.org/10.1093/jnci/djs357>

Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., ... Wiencke, J. K. (2011). DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. *Journal of the National Cancer Institute*, 103(2), 143–153. <https://doi.org/10.1093/jnci/djq497>

Chu, S.-H., Feng, D.-F., Ma, Y.-B., Zhang, H., Zhu, Z.-A., Li, Z.-Q., & Jiang, P.-C. (2011). Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. *Journal of Translational Medicine*, 9, 156. <https://doi.org/10.1186/1479-5876-9-156>

Clarke, L. E., Young, K. M., Hamilton, N. B., Li, H., Richardson, W. D., & Attwell, D. (2012). Properties and fate of oligodendrocyte progenitor cells in the corpus callosum, motor cortex, and piriform cortex of the mouse. *J Neurosci*, 32(24), 8173–8185. <https://doi.org/10.1523/JNEUROSCI.0928-12.2012>

Clements, M. P., Byrne, E., Camarillo Guerrero, L. F., Cattin, A.-L., Zakka, L., Ashraf, A., ... Parrinello, S. (2017). The Wound Microenvironment Reprograms Schwann Cells to Invasive Mesenchymal-like Cells to Drive Peripheral Nerve Regeneration. *Neuron*, 96(1), 98-114.e7. <https://doi.org/10.1016/j.neuron.2017.09.008>

Dawson, M. R., Polito, A., Levine, J. M., & Reynolds, R. (2003). NG2-expressing glial progenitor cells: An abundant and widespread population of cycling cells in the adult rat CNS. *Mol Cell Neurosci*, 24(2), 476–488.

de Ferra, F., Engh, H., Hudson, L., Kamholz, J., Puckett, C., Molineaux, S., & Lazzarini, R. A. (1985). Alternative splicing accounts for the four forms of myelin basic protein. *Cell*, 43(3), 721–727. [https://doi.org/10.1016/0092-8674\(85\)90245-4](https://doi.org/10.1016/0092-8674(85)90245-4)

De Raedt, T., Beert, E., Pasmant, E., Luscan, A., Brems, H., Ortonne, N., ... Cichowski, K. (2014). PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. *Nature*, 514(7521), 247–251. <https://doi.org/10.1038/nature13561>

de Souza, C. F., Sabedot, T. S., Malta, T. M., Stetson, L., Morozova, O., Sokolov, A., ... Noushmehr, H. (2018). A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. *Cell Reports*, 23(2), 637–651. <https://doi.org/10.1016/j.celrep.2018.03.107>

Deaton, A. M., & Bird, A. (2011). CpG islands and the regulation of transcription. *Genes & Development*, 25(10), 1010–1022. <https://doi.org/10.1101/gad.2037511>

Desplats, P., Spencer, B., Coffee, E., Patel, P., Michael, S., Patrick, C., ... Maslah, E. (2011). α -Synuclein Sequesters Dnmt1 from the Nucleus. *The Journal of Biological Chemistry*, 286(11), 9031–9037. <https://doi.org/10.1074/jbc.C110.212589>

Eden, S., & Cedar, H. (1994). Role of DNA methylation in the regulation of transcription. *Current Opinion in Genetics & Development*, 4(2), 255–259.

Egawa, N., Shindo, A., Hikawa, R., Kinoshita, H., Liang, A. C., Itoh, K., ... Arai, K. (2019). Differential roles of epigenetic regulators in the survival and differentiation of oligodendrocyte precursor cells. *Glia*, 67(4), 718–728. <https://doi.org/10.1002/glia.23567>

Emery, B., Agalliu, D., Cahoy, J. D., Watkins, T. A., Dugas, J. C., Mulinyawe, S. B., ... Barres, B. A. (2009). Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. *Cell*, 138(1), 172–185. <https://doi.org/10.1016/j.cell.2009.04.031>

Evans, D. G. R., Baser, M. E., McGaughran, J., Sharif, S., Howard, E., & Moran, A. (2002). Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *Journal of Medical Genetics*, 39(5), 311–314. <https://doi.org/10.1136/jmg.39.5.311>

Fan, G., Beard, C., Chen, R. Z., Csankovszki, G., Sun, Y., Siniaia, M., ... Jaenisch, R. (2001). DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. *J Neurosci*, 21(3), 788–797. (11157065).

Fan, Guoping, Martinowich, K., Chin, M. H., He, F., Fouse, S. D., Hutnick, L., ... Sun, Y. E. (2005). DNA methylation controls the timing of astroglialogenesis through regulation of JAK-STAT signaling. *Development*, 132(15), 3345–3356. <https://doi.org/10.1242/dev.01912>

Fancy, S. P. J., Harrington, E. P., Yuen, T. J., Silbereis, J. C., Zhao, C., Baranzini, S. E., ... Rowitch, D. H. (2011). Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. *Nature Neuroscience*, 14(8), 1009–1016. <https://doi.org/10.1038/nn.2855>

Farid, M., Demicco, E. G., Garcia, R., Ahn, L., Merola, P. R., Cioffi, A., & Maki, R. G. (2014). Malignant peripheral nerve sheath tumors. *The Oncologist*, 19(2), 193–201. <https://doi.org/10.1634/theoncologist.2013-0328>

Feber, A., Wilson, G. A., Zhang, L., Presneau, N., Idowu, B., Down, T. A., ... Beck, S. (2011). Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. *Genome Research*, 21(4), 515–524. <https://doi.org/10.1101/gr.109678.110>

Felsberg, J., Yan, P. S., Huang, T. H.-M., Milde, U., Schramm, J., Wiestler, O. D., ... Waha, A. (2006). DNA methylation and allelic losses on chromosome arm 14q in oligodendroglial tumours. *Neuropathology and Applied Neurobiology*, 32(5), 517–524. <https://doi.org/10.1111/j.1365-2990.2006.00759.x>

Feng, J., Zhou, Y., Campbell, S. L., Le, T., Li, E., Sweatt, J. D., ... Fan, G. (2010). Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. *Nat Neurosci*, 13(4), 423–430. <https://doi.org/10.1038/nn.2514>

Feng, Jian, Shao, N., Szulwach, K. E., Vialou, V., Huynh, J., Zhong, C., ... Nestler, E. J. (2015). Role of Tet1 and 5-hydroxymethylcytosine in cocaine action. *Nature Neuroscience*, 18(4), 536–544. <https://doi.org/10.1038/nn.3976>

Ficz, G., Branco, M. R., Seisenberger, S., Santos, F., Krueger, F., Hore, T. A., ... Reik, W. (2011). Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. *Nature*, 473(7347), 398–402. <https://doi.org/10.1038/nature10008>

Filbin, M. G., Tirosh, I., Hovestadt, V., Shaw, M. L., Escalante, L. E., Mathewson, N. D., ... Suvà, M. L. (2018). *Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq*. 6.

Fishbein, L., Eady, B., Sanek, N., Muir, D., & Wallace, M. R. (2005). Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells. *Cancer Genetics and Cytogenetics*, 157(2), 181–186. <https://doi.org/10.1016/j.cancergencyto.2004.08.016>

Frühbeis, C., Fröhlich, D., Kuo, W. P., Amphornrat, J., Thilemann, S., Saab, A. S., ... Krämer-Albers, E.-M. (2013). Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. *PLoS Biology*, 11(7), e1001604. <https://doi.org/10.1371/journal.pbio.1001604>

Gasparoni, G., Bultmann, S., Lutsik, P., Kraus, T. F. J., Sordon, S., Vlcek, J., ... Walter, J. (2018). DNA methylation analysis on purified neurons and glia dissects age and Alzheimer's disease-specific changes in the human cortex. *Epigenetics & Chromatin*, 11(1), 41. <https://doi.org/10.1186/s13072-018-0211-3>

Gautier, H. O. B., Evans, K. A., Volbracht, K., James, R., Sitnikov, S., Lundgaard, I., ... Káradóttir, R. T. (2015). Neuronal activity regulates remyelination via glutamate signalling to oligodendrocyte progenitors. *Nature Communications*, 6, 8518. <https://doi.org/10.1038/ncomms9518>

Gelfman, S., Cohen, N., Yearim, A., & Ast, G. (2013). DNA-methylation effect on cotranscriptional splicing is dependent on GC architecture of the exon-intron structure. *Genome Research*, 23(5), 789–799. <https://doi.org/10.1101/gr.143503.112>

Ghosh, A., Manrique-Hoyos, N., Voigt, A., Schulz, J. B., Kreutzfeldt, M., Merkler, D., & Simons, M. (2011). Targeted Ablation of Oligodendrocytes Triggers Axonal Damage. *PLoS ONE*, 6(7). <https://doi.org/10.1371/journal.pone.0022735>

Globisch, D., Münzel, M., Müller, M., Michalakis, S., Wagner, M., Koch, S., ... Carell, T. (2010). Tissue Distribution of 5-Hydroxymethylcytosine and Search for Active Demethylation Intermediates. *PLOS ONE*, 5(12), e15367. <https://doi.org/10.1371/journal.pone.0015367>

Glowacka, W. K., Jain, H., Okura, M., Maimaitiming, A., Mamatjan, Y., Nejad, R., ... Kongkham, P. (2018). 5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. *Acta Neuropathologica*, 135(4), 617–634. <https://doi.org/10.1007/s00401-018-1821-3>

Goll, M. G., & Bestor, T. H. (2005). Eukaryotic Cytosine Methyltransferases. *Annual Review of Biochemistry*, 74(1), 481–514. <https://doi.org/10.1146/annurev.biochem.74.010904.153721>

Gomez-Sanchez, J. A., Pilch, K. S., van der Lans, M., Fazal, S. V., Benito, C., Wagstaff, L. J., ... Jessen, K. R. (2017). After Nerve Injury, Lineage Tracing Shows That Myelin and Remak Schwann Cells Elongate Extensively and Branch to Form Repair Schwann Cells, Which Shorten Radically on Remyelination. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 37(37), 9086–9099. <https://doi.org/10.1523/JNEUROSCI.1453-17.2017>

Gonzalez-Gomez, P., Bello, M. J., Alonso, M. E., Lomas, J., Arjona, D., Campos, J. M. de, ... Rey, J. A. (2003). CpG island methylation in sporadic and neurofibromatosis type 2-associated schwannomas. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, 9(15), 5601–5606.

Gonzalez-Gomez, P., Bello, M. J., Arjona, D., Alonso, M. E., Lomas, J., De Campos, J. M., ... Rey, J. A. (2003). Aberrant CpG island methylation in neurofibromas and neurofibrosarcomas. *Oncology Reports*, 10(5), 1519–1523. <https://doi.org/10.3892/or.10.5.1519>

Grubinska, B., Laszkiewicz, I., Royland, J., Wiggins, R. C., & Konat, G. W. (1994). Differentiation-specific demethylation of myelin associated glycoprotein gene in cultured oligodendrocytes. *Journal of Neuroscience Research*, 39(3), 233–242. <https://doi.org/10.1002/jnr.490390302>

Guo, H., Zhu, P., Yan, L., Li, R., Hu, B., Lian, Y., ... Qiao, J. (2014). The DNA methylation landscape of human early embryos. *Nature*, 511(7511), 606–610. <https://doi.org/10.1038/nature13544>

Harder, A., Rosche, M., Reuss, D. E., Holtkamp, N., Uhlmann, K., Friedrich, R., ... von Deimling, A. (2004). Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours. *European Journal of Cancer (Oxford, England: 1990)*, 40(18), 2820–2828. <https://doi.org/10.1016/j.ejca.2004.07.021>

Hashimoto, H., Zhang, X., & Cheng, X. (2012). Excision of thymine and 5-hydroxymethyluracil by the MBD4 DNA glycosylase domain: Structural basis and implications for active DNA demethylation. *Nucleic Acids Research*, 40(17), 8276–8284. <https://doi.org/10.1093/nar/gks628>

Hatada, I., Namihira, M., Morita, S., Kimura, M., Horii, T., & Nakashima, K. (2008). Astrocyte-Specific Genes Are Generally Demethylated in Neural Precursor Cells Prior to Astrocytic Differentiation. *PLOS ONE*, 3(9), e3189. <https://doi.org/10.1371/journal.pone.0003189>

Hayakawa, K., Pham, L. D., Som, A. T., Lee, B. J., Guo, S., Lo, E. H., & Arai, K. (2011). Vascular endothelial growth factor regulates the migration of oligodendrocyte precursor cells. *J Neurosci*, 31(29), 10666–10670. <https://doi.org/10.1523/JNEUROSCI.1944-11.2011>

He, Y., Dupree, J., Wang, J., Sandoval, J., Li, J., Liu, H., ... Casaccia-Bonnel, P. (2007). The transcription factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation. *Neuron*, 55(2), 217–230. <https://doi.org/10.1016/j.neuron.2007.06.029>

He, Ye, Kim, J. Y., Dupree, J., Tewari, A., Melendez-Vasquez, C., Svaren, J., & Casaccia, P. (2010). Yy1 as a molecular link between neuregulin and transcriptional modulation of peripheral myelination. *Nature Neuroscience*, *13*(12), 1472–1480. <https://doi.org/10.1038/nn.2686>

Heiland, D. H., Ferrarese, R., Claus, R., Dai, F., Masilamani, A. P., Kling, E., ... Carro, M. S. (2016). C-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas. *Oncotarget*, *8*(4), 6940–6954. <https://doi.org/10.18632/oncotarget.14330>

Herbert, A. L., & Monk, K. R. (2017). Advances in myelinating glial cell development. *Current Opinion in Neurobiology*, *42*, 53–60. <https://doi.org/10.1016/j.conb.2016.11.003>

Hernandez, D. G., Nalls, M. A., Gibbs, J. R., Arepalli, S., van der Brug, M., Chong, S., ... Singleton, A. B. (2011). Distinct DNA methylation changes highly correlated with chronological age in the human brain. *Human Molecular Genetics*, *20*(6), 1164–1172. <https://doi.org/10.1093/hmg/ddq561>

Hilton, D. A., & Hanemann, C. O. (2014). Schwannomas and their pathogenesis. *Brain Pathology (Zurich, Switzerland)*, *24*(3), 205–220. <https://doi.org/10.1111/bpa.12125>

Hodges, E., Molaro, A., Dos Santos, C. O., Thekkat, P., Song, Q., Uren, P. J., ... Hannon, G. J. (2011). Directional DNA Methylation Changes and Complex Intermediate States Accompany Lineage Specificity in the Adult Hematopoietic Compartment. *Molecular Cell*, *44*(1), 17–28. <https://doi.org/10.1016/j.molcel.2011.08.026>

Horvath, S. (2013). DNA methylation age of human tissues and cell types. *Genome Biology*, *14*(10), R115. <https://doi.org/10.1186/gb-2013-14-10-r115>

Horvath, S., & Raj, K. (2018). DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nature Reviews Genetics*, *19*(6), 371–384. <https://doi.org/10.1038/s41576-018-0004-3>

Howng, S. Y., Avila, R. L., Emery, B., Traka, M., Lin, W., Watkins, T., ... Popko, B. (2010). ZFP191 is required by oligodendrocytes for CNS myelination. *Genes Dev*, *24*(3), 301–311. <https://doi.org/10.1101/gad.1864510>

Hu, N., Strobl-Mazzulla, P. H., & Bronner, M. E. (2014). Epigenetic Regulation in Neural Crest Development. *Developmental Biology*, *396*(2), 159–168. <https://doi.org/10.1016/j.ydbio.2014.09.034>

Hu, N., Strobl-Mazzulla, P. H., Simoes-Costa, M., Sánchez-Vásquez, E., & Bronner, M. E. (2014). DNA methyltransferase 3B regulates duration of neural crest production via repression of Sox10. *Proceedings of the National Academy of Sciences*, *111*(50), 17911–17916. <https://doi.org/10.1073/pnas.1318408111>

Hu, N., Strobl-Mazzulla, P., Sauka-Spengler, T., & Bronner, M. E. (2012). DNA methyltransferase3A as a molecular switch mediating the neural tube-to-neural crest fate transition. *Genes & Development*, *26*(21), 2380–2385. <https://doi.org/10.1101/gad.198747.112>

Huang, Y., & Rao, A. (2014). Connections between TET proteins and aberrant DNA modification in cancer. *Trends in Genetics: TIG*, *30*(10), 464–474. <https://doi.org/10.1016/j.tig.2014.07.005>

Hutnick, L. K., Golshani, P., Namihira, M., Xue, Z., Matynia, A., Yang, X. W., ... Fan, G. (2009). DNA hypomethylation restricted to the murine forebrain induces cortical degeneration and impairs postnatal neuronal maturation. *Hum Mol Genet*, *18*(15), 2875–2888. <https://doi.org/10.1093/hmg/ddp222>

Huynh, J. L., Garg, P., Thin, T. H., Yoo, S., Dutta, R., Trapp, B. D., ... Casaccia, P. (2014). Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. *Nature Neuroscience*, *17*(1), 121–130. <https://doi.org/10.1038/nn.3588>

International Multiple Sclerosis Genetics Consortium*†. (2019). Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science*, *365*(6460), eaav7188. <https://doi.org/10.1126/science.aav7188>

Jaffe, A. E., Gao, Y., Deep-Soboslay, A., Tao, R., Hyde, T. M., Weinberger, D. R., & Kleinman, J. E. (2015). Mapping DNA methylation across development, genotype and schizophrenia in the

human frontal cortex. *Nature Neuroscience*, advance online publication. <https://doi.org/10.1038/nn.4181>

Jessen, K. R., & Arthur-Farraj, P. (2019). Repair Schwann cell update: Adaptive reprogramming, EMT, and stemness in regenerating nerves. *Glia*, 67(3), 421–437. <https://doi.org/10.1002/glia.23532>

Jessen, K. R., & Mirsky, R. (2019). Schwann Cell Precursors; Multipotent Glial Cells in Embryonic Nerves. *Frontiers in Molecular Neuroscience*, 12. <https://doi.org/10.3389/fnmol.2019.00069>

Jessen, K. R., Mirsky, R., & Arthur-Farraj, P. (2015). The Role of Cell Plasticity in Tissue Repair: Adaptive Cellular Reprogramming. *Developmental Cell*, 34(6), 613–620. <https://doi.org/10.1016/j.devcel.2015.09.005>

Jia, D., Lin, W., Tang, H., Cheng, Y., Xu, K., He, Y., ... Dai, Q. (2019). Integrative analysis of DNA methylation and gene expression to identify key epigenetic genes in glioblastoma. *Aging*, 11(15), 5579–5592. <https://doi.org/10.18632/aging.102139>

Johnson, K. C., Houseman, E. A., King, J. E., Herrmann, K. M. von, Fadul, C. E., & Christensen, B. C. (2016). 5-Hydroxymethylcytosine localizes to enhancer elements and is associated with survival in glioblastoma patients. *Nature Communications*, 7, 13177. <https://doi.org/10.1038/ncomms13177>

Jones, M. J., Goodman, S. J., & Kobor, M. S. (2015). DNA methylation and healthy human aging. *Aging Cell*, 14(6), 924–932. <https://doi.org/10.1111/acel.12349>

Jones, P. A. (2012). Functions of DNA methylation: Islands, start sites, gene bodies and beyond. *Nature Reviews. Genetics*, 13(7), 484–492. <https://doi.org/10.1038/nrg3230>

Jordan, C. A., Friedrich, V. L., de Ferra, F., Weismiller, D. G., Holmes, K. V., & Dubois-Dalcq, M. (1990). Differential exon expression in myelin basic protein transcripts during central nervous system (CNS) remyelination. *Cell Mol Neurobiol*, 10(1), 3–18.

Kawaguchi, K., Oda, Y., Saito, T., Yamamoto, H., Takahira, T., Kobayashi, C., ... Tsuneyoshi, M. (2006). DNA hypermethylation status of multiple genes in soft tissue sarcomas. *Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc*, 19(1), 106–114. <https://doi.org/10.1038/modpathol.3800502>

Kevelam, S. H., Taube, J. R., van Spaendonk, R. M. L., Bertini, E., Sperle, K., Tarnopolsky, M., ... Wolf, N. I. (2015). Altered PLP1 splicing causes hypomyelination of early myelinating structures. *Annals of Clinical and Translational Neurology*, 2(6), 648–661. <https://doi.org/10.1002/acn3.203>

Kinde, B., Gabel, H. W., Gilbert, C. S., Griffith, E. C., & Greenberg, M. E. (2015). Reading the unique DNA methylation landscape of the brain: Non-CpG methylation, hydroxymethylation, and MeCP2. *Proceedings of the National Academy of Sciences of the United States of America*, 112(22), 6800–6806. <https://doi.org/10.1073/pnas.1411269112>

Kino, T., Takeshima, H., Nakao, M., Nishi, T., Yamamoto, K., Kimura, T., ... Ushio, Y. (2001). Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. *Genes to Cells: Devoted to Molecular & Cellular Mechanisms*, 6(5), 441–454.

Kozlenkov, A., Li, J., Apontes, P., Hurd, Y. L., Byne, W. M., Koonin, E. V., ... Dracheva, S. (2018). A unique role for DNA (hydroxy)methylation in epigenetic regulation of human inhibitory neurons. *Science Advances*, 4(9), eaau6190. <https://doi.org/10.1126/sciadv.aau6190>

Kriaucionis, S., & Heintz, N. (2009). The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain. *Science*, 324(5929), 929–930. <https://doi.org/10.1126/science.1169786>

Küspert, M., & Wegner, M. (2016). SomethiNG 2 talk about—Transcriptional regulation in embryonic and adult oligodendrocyte precursors. *Brain Research*, 1638, Part B, 167–182. <https://doi.org/10.1016/j.brainres.2015.07.024>

Lee, W., Teckie, S., Wiesner, T., Ran, L., Prieto Granada, C. N., Lin, M., ... Chi, P. (2014). PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. *Nature Genetics*, 46(11), 1227–1232. <https://doi.org/10.1038/ng.3095>

Lei, H., Oh, S. P., Okano, M., Juttermann, R., Goss, K. A., Jaenisch, R., & Li, E. (1996). De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. *Development*, 122(10), 3195–3205.

Lev Maor, G., Yearim, A., & Ast, G. (2015). The alternative role of DNA methylation in splicing regulation. *Trends in Genetics: TIG*. <https://doi.org/10.1016/j.tig.2015.03.002>

Li, E., Bestor, T. H., & Jaenisch, R. (1992). Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell*, 69(6), 915–926. (1606615).

Li, P., Marshall, L., Oh, G., Jakubowski, J. L., Groot, D., He, Y., ... Labrie, V. (2019). Epigenetic dysregulation of enhancers in neurons is associated with Alzheimer's disease pathology and cognitive symptoms. *Nature Communications*, 10(1), 2246. <https://doi.org/10.1038/s41467-019-10101-7>

Li, W., & Liu, M. (2011). Distribution of 5-Hydroxymethylcytosine in Different Human Tissues [Research article]. <https://doi.org/10.4061/2011/870726>

Liao, J., Karnik, R., Gu, H., Ziller, M. J., Clement, K., Tsankov, A. M., ... Meissner, A. (2015). Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. *Nature Genetics*, 47(5), 469–478. <https://doi.org/10.1038/ng.3258>

Ligon, K. L., Alberta, J. A., Kho, A. T., Weiss, J., Kwaan, M. R., Nutt, C. L., ... Rowitch, D. H. (2004). The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas. *Journal of Neuropathology & Experimental Neurology*, 63(5), 499–509. <https://doi.org/10.1093/jnen/63.5.499>

Lin, G., Mela, A., Guilfoyle, E., & Goldman, J. (2009). Neonatal and adult O4(+) oligodendrocyte lineage cells display different growth factor responses and different gene expression patterns. *J Neurosci Res*, 87(15), 3390–3402. <https://doi.org/10.1002/jnr.22065>

Lister, R., Mukamel, E. A., Nery, J. R., Urich, M., Puddifoot, C. A., Johnson, N. D., ... Ecker, J. R. (2013). Global epigenomic reconfiguration during mammalian brain development. *Science (New York, N.Y.)*, 341(6146), 1237905. <https://doi.org/10.1126/science.1237905>

Lister, R., Pelizzola, M., Dowen, R. H., Hawkins, R. D., Hon, G., Tonti-Filippini, J., ... Ecker, J. R. (2009). Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature*, 462(7271), 315–322. <https://doi.org/10.1038/nature08514>

Liu, Yanwei, Hu, H., Zhang, C., Wang, Z., Li, M., Zhang, W., & Jiang, T. (2015). Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation. *American Journal of Cancer Research*, 5(9), 2745–2755.

Liu, Yiwei, Zhang, X., Blumenthal, R. M., & Cheng, X. (2013). A common mode of recognition for methylated CpG. *Trends in Biochemical Sciences*, 38(4), 177–183. <https://doi.org/10.1016/j.tibs.2012.12.005>

Lu, Q. R., Sun, T., Zhu, Z., Ma, N., Garcia, M., Stiles, C. D., & Rowitch, D. H. (2002). Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. *Cell*, 109(1), 75–86.

Lu, Q. Richard, Park, J. K., Noll, E., Chan, J. A., Alberta, J., Yuk, D., ... Black, P. M. (2001). Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. *Proceedings of the National Academy of Sciences*, 98(19), 10851–10856. <https://doi.org/10.1073/pnas.181340798>

Luijten, M., Redeker, S., Van, M. N., Troost, D., Westerveld, A., & Hulsebos, T. J. (2000). Microsatellite instability and promoter methylation as possible causes of NF1 gene inactivation in neurofibromas. *European Journal of Human Genetics: EJHG*, 8(12), 939–945. <https://doi.org/10.1038/sj.ejhg.5200565>

Lyko, F. (2018). The DNA methyltransferase family: A versatile toolkit for epigenetic regulation. *Nature Reviews Genetics*, 19(2), 81–92. <https://doi.org/10.1038/nrg.2017.80>

Mancini, D. N., Singh, S. M., Archer, T. K., & Rodenhiser, D. I. (1999). Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors. *Oncogene*, *18*(28), 4108–4119. <https://doi.org/10.1038/sj.onc.1202764>

Marques, S., Zeisel, A., Codeluppi, S., Bruggen, D. van, Falcão, A. M., Xiao, L., ... Castelo-Branco, G. (2016). Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. *Science*, *352*(6291), 1326–1329. <https://doi.org/10.1126/science.aaf6463>

Martins-Taylor, K., Schroeder, D. I., LaSalle, J. M., Lalande, M., & Xu, R.-H. (2012). Role of DNMT3B in the regulation of early neural and neural crest specifiers. *Epigenetics*, *7*(1), 71–82. <https://doi.org/10.4161/epi.7.1.18750>

Masser, D. R., Hadad, N., Porter, H. L., Mangold, C. A., Unnikrishnan, A., Ford, M. M., ... Freeman, W. M. (2017). Sexually divergent DNA methylation patterns with hippocampal aging. *Aging Cell*, *16*(6), 1342–1352. <https://doi.org/10.1111/ace1.12681>

Masser, D. R., Hadad, N., Porter, H., Stout, M. B., Unnikrishnan, A., Stanford, D. R., & Freeman, W. M. (2018). Analysis of DNA modifications in aging research. *GeroScience*, *40*(1), 11–29. <https://doi.org/10.1007/s11357-018-0005-3>

Mastronardi, F. G., & Moscarello, M. A. (2005). Molecules affecting myelin stability: A novel hypothesis regarding the pathogenesis of multiple sclerosis. *Journal of Neuroscience Research*, *80*(3), 301–308. <https://doi.org/10.1002/jnr.20420>

Mastronardi, F. G., Noor, A., Wood, D. D., Paton, T., & Moscarello, M. A. (2007). Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. *Journal of Neuroscience Research*, *85*(9), 2006–2016. <https://doi.org/10.1002/jnr.21329>

Mastronardi, F. G., Wood, D. D., Mei, J., Raijmakers, R., Tseveleki, V., Dosch, H.-M., ... Moscarello, M. A. (2006). Increased Citrullination of Histone H3 in Multiple Sclerosis Brain and Animal Models of Demyelination: A Role for Tumor Necrosis Factor-Induced Peptidylarginine Deiminase 4 Translocation. *Journal of Neuroscience*, *26*(44), 11387–11396. <https://doi.org/10.1523/JNEUROSCI.3349-06.2006>

Maunakea, A. K., Chepelev, I., Cui, K., & Zhao, K. (2013). Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. *Cell Research*, *23*(11), 1256–1269. <https://doi.org/10.1038/cr.2013.110>

McKenzie, A. T., Moyon, S., Wang, M., Katsyv, I., Song, W.-M., Zhou, X., ... Zhang, B. (2017). Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer's disease. *Molecular Neurodegeneration*, *12*, 82. <https://doi.org/10.1186/s13024-017-0219-3>

McKenzie, I. A., Ohayon, D., Li, H., Faria, J. P. de, Emery, B., Tohyama, K., & Richardson, W. D. (2014). Motor skill learning requires active central myelination. *Science*, *346*(6207), 318–322. <https://doi.org/10.1126/science.1254960>

Meier, K., & Recillas-Targa, F. (2017). New insights on the role of DNA methylation from a global view. *Frontiers in Bioscience (Landmark Edition)*, *22*, 644–668.

Mendizabal, I., Berto, S., Usui, N., Toriumi, K., Chatterjee, P., Douglas, C., ... Yi, S. V. (2019). Cell type-specific epigenetic links to schizophrenia risk in the brain. *Genome Biology*, *20*(1), 135. <https://doi.org/10.1186/s13059-019-1747-7>

Michailov, G. V., Sereda, M. W., Brinkmann, B. G., Fischer, T. M., Haug, B., Birchmeier, C., ... Nave, K.-A. (2004). Axonal Neuregulin-1 Regulates Myelin Sheath Thickness. *Science*, *304*(5671), 700–703. <https://doi.org/10.1126/science.1095862>

Milutinovic, S., Zhuang, Q., Niveleau, A., & Szyf, M. (2003). Epigenomic stress response. Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes. *J Biol Chem*, *278*(17), 14985–14995. <https://doi.org/10.1074/jbc.M213219200>

Mogha, A., Benesh, A. E., Patra, C., Engel, F. B., Schöneberg, T., Liebscher, I., & Monk, K. R. (2013). Gpr126 functions in Schwann cells to control differentiation and myelination via G-

protein activation. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 33(46), 17976–17985. <https://doi.org/10.1523/JNEUROSCI.1809-13.2013>

Monk, K. R., Feltri, M. L., & Taveggia, C. (2015). New insights on Schwann cell development. *Glia*, 63(8), 1376–1393. <https://doi.org/10.1002/glia.22852>

Monk, K. R., Naylor, S. G., Glenn, T. D., Mercurio, S., Perlin, J. R., Dominguez, C., ... Talbot, W. S. (2009). A G protein-coupled receptor is essential for Schwann cells to initiate myelination. *Science (New York, N.Y.)*, 325(5946), 1402–1405. <https://doi.org/10.1126/science.1173474>

Moscarello, M. A., Wood, D. D., Ackerley, C., & Boulias, C. (1994). Myelin in multiple sclerosis is developmentally immature. *The Journal of Clinical Investigation*, 94(1), 146–154. <https://doi.org/10.1172/JCI117300>

Moyon, S., Dubessy, A. L., Aigrot, M. S., Trotter, M., Huang, J. K., Dauphinot, L., ... Lubetzki, C. (2015). Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 35(1), 4–20. <https://doi.org/10.1523/JNEUROSCI.0849-14.2015>

Moyon, S., Frawley, R., Marshall-Phelps, K. L., Kegel, L., Bostrand, S. M., Sadowski, B., ... Casaccia, P. (2019). TET1-mediated DNA hydroxy-methylation regulates adult remyelination. *BioRxiv*, 819995. <https://doi.org/10.1101/819995>

Moyon, S., Huynh, J., Yoo, S., Dutta, D., Zhang, F., Ma, D., ... Casaccia, P. (2016). Functional characterization of DNA methylation in the oligodendrocyte lineage. *Cell Reports*.

Moyon, S., Ma, D., Huynh, J. L., Coutts, D. J. C., Zhao, C., Casaccia, P., & Franklin, R. J. M. (2017). Efficient Remyelination Requires DNA Methylationxs. *ENeuro*, ENEURO.0336-16.2017. <https://doi.org/10.1523/ENEURO.0336-16.2017>

Nagaraja, S., Vitanza, N. A., Woo, P., Taylor, K. R., Liu, F., Zhang, L., ... Monje, M. (2017). Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. *Cancer Cell*, 31(5), 635–652.e6. <https://doi.org/10.1016/j.ccell.2017.03.011>

Nakatani, H., Martin, E., Hassani, H., Clavairoly, A., Maire, C. L., Viadieu, A., ... Parras, C. (2013). Ascl1/Mash1 Promotes Brain Oligodendrogenesis during Myelination and Remyelination. *J Neurosci*, 33(23), 9752–9768. <https://doi.org/10.1523/JNEUROSCI.0805-13.2013>

Namihira, M., Kohyama, J., Semi, K., Sanosaka, T., Deneen, B., Taga, T., & Nakashima, K. (2009). Committed Neuronal Precursors Confer Astrocytic Potential on Residual Neural Precursor Cells. *Developmental Cell*, 16(2), 245–255. <https://doi.org/10.1016/j.devcel.2008.12.014>

Nasrabad, S. E., Rizvi, B., Goldman, J. E., & Brickman, A. M. (2018). White matter changes in Alzheimer's disease: A focus on myelin and oligodendrocytes. *Acta Neuropathologica Communications*, 6, 22. <https://doi.org/10.1186/s40478-018-0515-3>

Natalie Wu, L. M., & Lu, Q. R. (2019). Therapeutic targets for malignant peripheral nerve sheath tumors. *Future Neurology*, 14(1), FNL7. <https://doi.org/10.2217/fnl-2018-0026>

Nave, K. A., Lai, C., Bloom, F. E., & Milner, R. J. (1987). Splice site selection in the proteolipid protein (PLP) gene transcript and primary structure of the DM-20 protein of central nervous system myelin. *Proc Natl Acad Sci U S A*, 84(16), 5665–5669.

Nestor, C. E., Ottaviano, R., Reddington, J., Sproul, D., Reinhardt, D., Dunican, D., ... Meehan, R. R. (2012). Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. *Genome Research*, 22(3), 467–477. <https://doi.org/10.1101/gr.126417.111>

Nguyen, M. V. C., Felice, C. A., Du, F., Covey, M. V., Robinson, J. K., Mandel, G., & Ballas, N. (2013). Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 33(48), 18764–18774. <https://doi.org/10.1523/JNEUROSCI.2657-13.2013>

Oh, J.-E., Ohta, T., Satomi, K., Foll, M., Durand, G., McKay, J., ... Ohgaki, H. (2015). Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas. *Journal of Neuropathology and Experimental Neurology*, 74(10), 952–959. <https://doi.org/10.1097/NEN.0000000000000238>

Ohba, S., & Hirose, Y. (2018). Association between mutant IDHs and tumorigenesis in gliomas. *Medical Molecular Morphology*, 51(4), 194–198. <https://doi.org/10.1007/s00795-018-0189-8>

Ohgaki, H., & Kleihues, P. (2005). Epidemiology and etiology of gliomas. *Acta Neuropathologica*, 109(1), 93–108. <https://doi.org/10.1007/s00401-005-0991-y>

Okano, M., Xie, S., & Li, E. (1998). Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. *Nature Genetics*, 19(3), 219–220. <https://doi.org/10.1038/890>

Oluich, L. J., Stratton, J. A., Xing, Y. L., Ng, S. W., Cate, H. S., Sah, P., ... Merson, T. D. (2012). Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination. *J Neurosci*, 32(24), 8317–8330. <https://doi.org/10.1523/JNEUROSCI.1053-12.2012>

Ono, T., Uehara, Y., Kurishita, A., Tawa, R., & Sakurai, H. (1993). Biological significance of DNA methylation in the ageing process. *Age Ageing*, 22(1), S34–43.

Oswald, J., Engemann, S., Lane, N., Mayer, W., Olek, A., Fundele, R., ... Walter, J. (2000). Active demethylation of the paternal genome in the mouse zygote. *Current Biology*, 10(8), 475–478. [https://doi.org/10.1016/S0960-9822\(00\)00448-6](https://doi.org/10.1016/S0960-9822(00)00448-6)

Parfejevs, V., Antunes, A. T., & Sommer, L. (2018). Injury and stress responses of adult neural crest-derived cells. *Developmental Biology*, 444 Suppl 1, S356–S365. <https://doi.org/10.1016/j.ydbio.2018.05.011>

Petersen, S. C., Luo, R., Liebscher, I., Giera, S., Jeong, S.-J., Mogha, A., ... Monk, K. R. (2015). The adhesion GPCR GPR126 has distinct, domain-dependent functions in Schwann cell development mediated by interaction with laminin-211. *Neuron*, 85(4), 755–769. <https://doi.org/10.1016/j.neuron.2014.12.057>

Pham, L.-D. D., Hayakawa, K., Seo, J. H., Nguyen, M.-N., Som, A. T., Lee, B. J., ... Arai, K. (2012). Crosstalk between oligodendrocytes and cerebral endothelium contributes to vascular remodeling after white matter injury. *Glia*, 60(6), 875–881. <https://doi.org/10.1002/glia.22320>

Pringle, N. P., Mudhar, H. S., Collarini, E. J., & Richardson, W. D. (1992). PDGF receptors in the rat CNS: during late neurogenesis, PDGF alpha-receptor expression appears to be restricted to glial cells of the oligodendrocyte lineage. *Development*, 115(2), 535–551.

Ransom, B. R., Yamate, C. L., Black, J. A., & Waxman, S. G. (1985). Rat optic nerve: Disruption of gliogenesis with 5-azacytidine during early postnatal development. *Brain Research*, 337(1), 41–49.

Rasmussen, K. D., & Helin, K. (2016). Role of TET enzymes in DNA methylation, development, and cancer. *Genes & Development*, 30(7), 733–750. <https://doi.org/10.1101/gad.276568.115>

Ratner, N., & Miller, S. J. (2015). A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor. *Nature Reviews. Cancer*, 15(5), 290–301. <https://doi.org/10.1038/nrc3911>

Sanosaka, T., Imamura, T., Hamazaki, N., Chai, M., Igarashi, K., Ideta-Otsuka, M., ... Nakashima, K. (2017). DNA Methylome Analysis Identifies Transcription Factor-Based Epigenomic Signatures of Multilineage Competence in Neural Stem/Progenitor Cells. *Cell Reports*, 20(12), 2992–3003. <https://doi.org/10.1016/j.celrep.2017.08.086>

Schübeler, D. (2015). Function and information content of DNA methylation. *Nature*, 517(7534), 321–326. <https://doi.org/10.1038/nature14192>

Semick, S. A., Bharadwaj, R. A., Collado-Torres, L., Tao, R., Shin, J. H., Deep-Soboslay, A., ... Mattay, V. S. (2019). Integrated DNA methylation and gene expression profiling across multiple brain regions implicate novel genes in Alzheimer's disease. *Acta Neuropathologica*. <https://doi.org/10.1007/s00401-019-01966-5>

Serra, E., Puig, S., Otero, D., Gaona, A., Kruyer, H., Ars, E., ... Lázaro, C. (1997). Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. *American Journal of Human Genetics*, 61(3), 512–519. <https://doi.org/10.1086/515504>

Sharma, S., Kelly, T. K., & Jones, P. A. (2010). Epigenetics in cancer. *Carcinogenesis*, 31(1), 27–36. <https://doi.org/10.1093/carcin/bgp220>

Shen, S., Sandoval, J., Swiss, V., Li, J., Dupree, J., Franklin, R., & Casaccia-Bonnel, P. (2008). Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. *Nat Neurosci*, 11(9), 1024–1034. <https://doi.org/10.1038/nn.2172> [pii] 10.1038/nn.2172

Shoshan, Y., Nishiyama, A., Chang, A., Mörk, S., Barnett, G. H., Cowell, J. K., ... Staugaitis, S. M. (1999). Expression of oligodendrocyte progenitor cell antigens by gliomas: Implications for the histogenesis of brain tumors. *Proceedings of the National Academy of Sciences*, 96(18), 10361–10366. <https://doi.org/10.1073/pnas.96.18.10361>

Shu, T., Butz, K. G., Plachez, C., Gronostajski, R. M., & Richards, L. J. (2003). Abnormal development of forebrain midline glia and commissural projections in Nfia knock-out mice. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 23(1), 203–212.

Smith, Z. D., & Meissner, A. (2013). DNA methylation: Roles in mammalian development. *Nature Reviews Genetics*, 14(3), 204–220. <https://doi.org/10.1038/nrg3354>

Spitzer, S. O., Sitnikov, S., Kamen, Y., Evans, K. A., Kronenberg-Versteeg, D., Dietmann, S., ... Káradóttir, R. T. (2019). Oligodendrocyte Progenitor Cells Become Regionally Diverse and Heterogeneous with Age. *Neuron*, 0(0). <https://doi.org/10.1016/j.neuron.2018.12.020>

Stadler, M. B., Murr, R., Burger, L., Ivanek, R., Lienert, F., Schöler, A., ... Schübeler, D. (2011). DNA-binding factors shape the mouse methylome at distal regulatory regions. *Nature*, 480(7378), 490–495. <https://doi.org/10.1038/nature10716>

Stierli, S., Napoli, I., White, I. J., Cattin, A.-L., Monteza Cabrejos, A., Garcia Calavia, N., ... Lloyd, A. C. (2018). The regulation of the homeostasis and regeneration of peripheral nerve is distinct from the CNS and independent of a stem cell population. *Development (Cambridge, England)*, 145(24). <https://doi.org/10.1242/dev.170316>

Stubbs, T. M., Bonder, M. J., Stark, A.-K., Krueger, F., Bolland, D., Butcher, G., ... BI Ageing Clock Team. (2017). Multi-tissue DNA methylation age predictor in mouse. *Genome Biology*, 18(1), 68. <https://doi.org/10.1186/s13059-017-1203-5>

Suzuki, M. M., & Bird, A. (2008). DNA methylation landscapes: Provocative insights from epigenomics. *Nature Reviews Genetics*, 9(6), 465–476. <https://doi.org/10.1038/nrg2341>

Szulwach, K. E., Li, X., Li, Y., Song, C.-X., Han, J. W., Kim, S., ... Jin, P. (2011). Integrating 5-hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells. *PLoS Genetics*, 7(6), e1002154. <https://doi.org/10.1371/journal.pgen.1002154>

Szulwach, K. E., Li, X., Li, Y., Song, C.-X., Wu, H., Dai, Q., ... Jin, P. (2011). 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. *Nature Neuroscience*, 14(12), 1607–1616. <https://doi.org/10.1038/nn.2959>

Takizawa, T., Nakashima, K., Namihira, M., Ochiai, W., Uemura, A., Yanagisawa, M., ... Taga, T. (2001). DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain. *Developmental Cell*, 1(6), 749–758.

Taveggia, C., Zanazzi, G., Petrylak, A., Yano, H., Rosenbluth, J., Einheber, S., ... Salzer, J. L. (2005). Neuregulin-1 type III determines the ensheathment fate of axons. *Neuron*, 47(5), 681–694. <https://doi.org/10.1016/j.neuron.2005.08.017>

Tawa, R., Ono, T., Kurishita, A., Okada, S., & Hirose, S. (1990). Changes of DNA methylation level during pre- and postnatal periods in mice. *Differentiation*, 45(1), 44–48.

Teter, B., Rozovsky, I., Krohn, K., Anderson, C., Osterburg, H., & Finch, C. (1996). Methylation of the glial fibrillary acidic protein gene shows novel biphasic changes during brain development. *Glia*, 17(3), 195–205. [https://doi.org/10.1002/\(SICI\)1098-1136\(199607\)17:3<195::AID-GLIA2>3.0.CO;2-0](https://doi.org/10.1002/(SICI)1098-1136(199607)17:3<195::AID-GLIA2>3.0.CO;2-0)

Torres-Martín, M., Lassaletta, L., de Campos, J. M., Isla, A., Pinto, G. R., Burbano, R. R., ... Rey, J. A. (2015). Genome-wide methylation analysis in vestibular schwannomas shows putative mechanisms of gene expression modulation and global hypomethylation at the HOX

gene cluster. *Genes, Chromosomes & Cancer*, 54(4), 197–209. <https://doi.org/10.1002/gcc.22232>

Uhlmann, K., Rohde, K., Zeller, C., Szymas, J., Vogel, S., Marczinek, K., ... Laird, P. W. (2003). Distinct methylation profiles of glioma subtypes. *International Journal of Cancer*, 106(1), 52–59. <https://doi.org/10.1002/ijc.11175>

Unnikrishnan, A., Freeman, W. M., Jackson, J., Wren, J. D., Porter, H., & Richardson, A. (2019). The role of DNA methylation in epigenetics of aging. *Pharmacology & Therapeutics*, 195, 172–185. <https://doi.org/10.1016/j.pharmthera.2018.11.001>

Unruh, D., Zewde, M., Buss, A., Drumm, M. R., Tran, A. N., Scholtens, D. M., & Horbinski, C. (2019). Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. *Scientific Reports*, 9(1), 8946. <https://doi.org/10.1038/s41598-019-45346-1>

Unterberger, A., Andrews, S. D., Weaver, I. C., & Szyf, M. (2006). DNA methyltransferase 1 knockdown activates a replication stress checkpoint. *Mol Cell Biol*, 26(20), 7575–7586. <https://doi.org/10.1128/mcb.01887-05>

Varela-Rey, M., Iruarizaga-Lejarreta, M., Lozano, J. J., Aransay, A. M., Fernandez, A. F., Lavin, J. L., ... Woodhoo, A. (2014). S-adenosylmethionine levels regulate the schwann cell DNA methylome. *Neuron*, 81(5), 1024–1039. <https://doi.org/10.1016/j.neuron.2014.01.037>

Venkataramani, V., Tanev, D. I., Strahle, C., Studier-Fischer, A., Fankhauser, L., Kessler, T., ... Kuner, T. (2019). Glutamatergic synaptic input to glioma cells drives brain tumour progression. *Nature*, 573(7775), 532–538. <https://doi.org/10.1038/s41586-019-1564-x>

Venkatesh, H. S., Morishita, W., Geraghty, A. C., Silverbush, D., Gillespie, S. M., Arzt, M., ... Monje, M. (2019). Electrical and synaptic integration of glioma into neural circuits. *Nature*, 573(7775), 539–545. <https://doi.org/10.1038/s41586-019-1563-y>

Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., ... Hayes, D. N. (2010). Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell*, 17(1), 98–110. <https://doi.org/10.1016/j.ccr.2009.12.020>

Wan, J., Oliver, V. F., Zhu, H., Zack, D. J., Qian, J., & Merbs, S. L. (2013). Integrative analysis of tissue-specific methylation and alternative splicing identifies conserved transcription factor binding motifs. *Nucleic Acids Research*, 41(18), 8503–8514. <https://doi.org/10.1093/nar/gkt652>

Watanabe, Y., & Maekawa, M. (2010). Methylation of DNA in cancer. *Advances in Clinical Chemistry*, 52, 145–167.

Wolswijk, G., & Noble, M. (1989). Identification of an adult-specific glial progenitor cell. *Development*, 105(2), 387–400.

Wu, H., Coskun, V., Tao, J., Xie, W., Ge, W., Yoshikawa, K., ... Sun, Y. E. (2010). Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. *Science (New York, N.Y.)*, 329(5990), 444–448. <https://doi.org/10.1126/science.1190485>

Wu, H., & Zhang, Y. (2011). Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. *Genes & Development*, 25(23), 2436–2452. <https://doi.org/10.1101/gad.179184.111>

Wu, L. M. N., Deng, Y., Wang, J., Zhao, C., Wang, J., Rao, R., ... Lu, Q. R. (2018). Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. *Cancer Cell*, 33(2), 292–308.e7. <https://doi.org/10.1016/j.ccell.2018.01.005>

Wu, Z., Huang, K., Yu, J., Le, T., Namihira, M., Liu, Y., ... Fan, G. (2012). Dnmt3a regulates both proliferation and differentiation of mouse neural stem cells. *Journal of Neuroscience Research*, 90(10), 1883–1891. <https://doi.org/10.1002/jnr.23077>

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., ... Bigner, D. D. (2009). IDH1 and IDH2 Mutations in Gliomas. *New England Journal of Medicine*, 360(8), 765–773. <https://doi.org/10.1056/NEJMoa0808710>

Yearim, A., Gelfman, S., Shayevitch, R., Melcer, S., Glaich, O., Mallm, J.-P., ... Ast, G. (2015). HP1 Is Involved in Regulating the Global Impact of DNA Methylation on Alternative Splicing. *Cell Reports*, 10(7), 1122–1134. <https://doi.org/10.1016/j.celrep.2015.01.038>

Yin, Y., Morgunova, E., Jolma, A., Kaasinen, E., Sahu, B., Khund-Sayeed, S., ... Taipale, J. (2017). Impact of cytosine methylation on DNA binding specificities of human transcription factors. *Science (New York, N.Y.)*, 356(6337). <https://doi.org/10.1126/science.aaj2239>

Young, K. M., Psachoulia, K., Tripathi, R. B., Dunn, S. J., Cossell, L., Attwell, D., ... Richardson, W. D. (2013). Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling. *Neuron*, 77(5), 873–885. <https://doi.org/10.1016/j.neuron.2013.01.006>

Zeng, Q., Michael, I. P., Zhang, P., Saghafinia, S., Knott, G., Jiao, W., ... Hanahan, D. (2019). Synaptic proximity enables NMDAR signalling to promote brain metastasis. *Nature*, 573(7775), 526–531. <https://doi.org/10.1038/s41586-019-1576-6>

Zhang, J., Yang, J.-H., Quan, J., Kang, X., Wang, H.-J., & Dai, P.-G. (2016). Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas. *Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine*, 37(10), 13571–13579. <https://doi.org/10.1007/s13277-016-5153-4>

Zhang, M., Wang, J., Zhang, K., Lu, G., Xu, L., Ren, K., ... Zhao, X. (2019). TET1-mediated Oligodendrocyte Homeostasis Regulates Myelination and Synaptic Functions. *BioRxiv*, 821496. <https://doi.org/10.1101/821496>

Zhang, M., Wang, Y., Jones, S., Sausen, M., McMahon, K., Sharma, R., ... Bettegowda, C. (2014). Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. *Nature Genetics*, 46(11), 1170–1172. <https://doi.org/10.1038/ng.3116>

Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O’Keeffe, S., ... Wu, J. Q. (2014). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, 34(36), 11929–11947. <https://doi.org/10.1523/JNEUROSCI.1860-14.2014>

Zhao, X., Dai, J., Ma, Y., Mi, Y., Cui, D., Ju, G., ... Jin, W. (2014). Dynamics of ten-eleven translocation hydroxylase family proteins and 5-hydroxymethylcytosine in oligodendrocyte differentiation. *Glia*, 62(6), 914–926. <https://doi.org/10.1002/glia.22649>

Zhu, H., Wang, G., & Qian, J. (2016). Transcription factors as readers and effectors of DNA methylation. *Nature Reviews. Genetics*, 17(9), 551–565. <https://doi.org/10.1038/nrg.2016.83>

Ziller, M. J., Gu, H., Müller, F., Donaghey, J., Tsai, L. T.-Y., Kohlbacher, O., ... Meissner, A. (2013). Charting a dynamic DNA methylation landscape of the human genome. *Nature*, 500(7463), 477–481. <https://doi.org/10.1038/nature12433>

Zong, H., Parada, L. F., & Baker, S. J. (2015). Cell of Origin for Malignant Gliomas and Its Implication in Therapeutic Development. *Cold Spring Harbor Perspectives in Biology*, 7(5), a020610. <https://doi.org/10.1101/cshperspect.a020610>